Peeters Protides of the Biological Fluids

Proceedings of the Thirty-Second Colloquium, 1984
1. Auflage 2014
ISBN: 978-1-4832-7966-4
Verlag: Elsevier Science & Techn.
Format: PDF
Kopierschutz: 1 - PDF Watermark

E-Book, Englisch, Band Volume 32, 1236 Seiten, Web PDF

Reihe: Protides of the Biological Fluids

An International Review Series Devoted to Proteins and Related Studies, Volume 32: Protides of the Biological Fluids documents the proceedings of the 32nd Colloquium held in 1984. This compilation is organized into three parts. Part I begins with an introduction to the defense mechanism of immunoglobulins, followed by a description of enzymes and proteins, such as lactoperoxidase and lactoferrin. The secretions that include CSF, colostrum, milk, female and male genital secretions, saliva, gastrointestinal juice, nasal and bronchoalveolar secretions, tears and synovial fluid are also elaborated. The tumor markers, which include ferritin, CEA, and TPA are dealt with in Part II. The immunotoxins, tumor imaging, and lymphoid malignancies are also covered. Part III is devoted to the advances in the separation of protides, including the staining procedure for protein detection, two-dimensional electrophoresis, and HPLC and affinity chromatography. This book is valuable to biology students and clinicians of disciplines related to advances in the protein field.

Autoren/Hrsg.

Peeters, H.

Inhaltsverzeichnis

1;Front Cover;1
2;Protides of the Biological Fluids;4
3;Copyright Page;5
4;Table of Contents;6
5;PREFACE;34
6;ACKNOWLEDGEMENTS;36
7;Part I: The Thirteenth Arne Tiselius Memorial Lecture;38
7.1;CHAPTER 1. LOW MOLECULAR WEIGHT (LMW) URINARY PROTEINS;40
7.1.1;INTRODUCTION;40
7.1.2;ß2-MICROGLOBUL IN (ß2m);41
7.1.3;a2-MICROGLOBUL IN (a2m);44
7.1.4;a1-MICROGLOBUL IN (a1m);45
7.1.5;POST-GAMMA GLOBUL IN (p-.);46
7.1.6;ACKNOWLEDGEMENT;47
7.1.7;REFERENCES;48
7.2;SECTION A: Proteins in Secretions;52
7.2.1;A.1. Immunoglobulins;54
7.2.1.1;CHAPTER 2. A MODEL FOR ANALYSIS OF PROTEIN DEFENSE MECHANISMS IN SECRETIONS;54
7.2.1.1.1;ABSTRACT;54
7.2.1.1.2;KEYWORDS;54
7.2.1.1.3;INTRODUCTION;54
7.2.1.1.4;THEORETICAL ANALYSIS;55
7.2.1.1.5;PRACTICAL APPLICATIONS;56
7.2.1.1.6;DISCUSSION;57
7.2.1.1.7;ACKNOWLEDGEMENTS;57
7.2.1.1.8;REFERENCES;57
7.2.1.2;CHAPTER 3. LOCAL PROTEIN SYNTHESIS AND PASSIVE TRANSFER IN HUMAN BODY FLUID FORMATION;58
7.2.1.2.1;References;61
7.2.1.3;CHAPTER 4. EVIDENCE FOR A COMMON MUCOSAL IMMUNE SYSTEM IN HUMANS;62
7.2.1.3.1;ABSTRACT;62
7.2.1.3.2;KEY WORDS;62
7.2.1.3.3;INTRODUCTION;62
7.2.1.3.4;NATURALLY-OCCURING S-IgA ANTIBODIES IN SECRETIONS OF GLANDS NOT DIRECTLY STIMULATED WITH ANTIGENS;63
7.2.1.3.5;INDUCTION OF S-IgA ANTIBODIES IN MILK, TEARS, AND SALIVA BY INGESTION OF BACTERIAL ANTIGENS.;63
7.2.1.3.6;DETECTION IN PERIPHERAL BLOOD OF LYMPHOID CELLS WITH POTENTIAL TO PRODUCE POLYMERIC IgA AND SPECIFIC ANTIBODIES TO INGESTED ANTIGEN.;63
7.2.1.3.7;CONCLUSIONS AND FUTURE DIRECTIONS;65
7.2.1.3.8;REFERENCES;65
7.2.1.3.9;ACKNOWLEDGMENT;66
7.2.1.4;CHAPTER 5. COMPLEMENT REGULATION IN TEARS;68
7.2.1.4.1;ABSTRACT;68
7.2.1.4.2;KEYWORDS;68
7.2.1.4.3;INTRODUCTION;68
7.2.1.4.4;MATERIALS AND METHODS;68
7.2.1.4.5;RESULTS;69
7.2.1.4.6;DISCUSSION;71
7.2.1.4.7;ACKNOWLEDGEMENTS;71
7.2.1.4.8;REFERENCES;71
7.2.1.5;CHAPTER 6. BIOSYNTHESIS OF THE IgA DIMER RECEPTOR;72
7.2.1.5.1;ABSTRACT;72
7.2.1.5.2;KEYWORDS;72
7.2.1.5.3;INTRODUCTION;72
7.2.1.5.4;RESULTS;74
7.2.1.5.5;DISCUSSION;75
7.2.1.5.6;REFERENCES;75
7.2.1.6;CHAPTER 7. BINDING OF arMICROGLOBULIN TO IgA;76
7.2.1.6.1;ABSTRACT;76
7.2.1.6.2;KEYWORDS;76
7.2.1.6.3;INTRODUCTION;76
7.2.1.6.4;PATIENTS AND METHODS;76
7.2.1.6.5;RESULTS AND DISCUSSION;78
7.2.1.6.6;REFERENCES;79
7.2.1.7;CHAPTER 8. EVIDENCE FOR MIGRATION OF IgA BEARING LYMPHOCYTES BETWEEN PERIPHERAL MUSCOSAL SITES;80
7.2.1.7.1;ABSTRACT;80
7.2.1.7.2;INTRODUCTION;80
7.2.1.7.3;MATERIALS AND METHODS;80
7.2.1.7.4;RESULTS;81
7.2.1.7.5;DISCUSSION;81
7.2.1.7.6;ACKNOWLEDGEMENTS;83
7.2.1.7.7;REFERENCES;83
7.2.1.8;CHAPTER 9. ORAL ADJUVANTS ENHANCE SALIVARY IgA RESPONSES TO PURIFIED STREPTOCOCCUS MUTANS ANTIGENS;84
7.2.1.8.1;ABSTRACT;84
7.2.1.8.2;KEYWORDS;84
7.2.1.8.3;INTRODUCTION;84
7.2.1.8.4;EFFECT OF S. MUTANS ANTIGEN FORM AND MOLECULAR ADJUVANT ON THE INDUCTION OF IgA RESPONSES AND CARIES IMMUNITY;85
7.2.1.8.5;S. MUTANS ANTIGENS IMPORTANT IN CARIES IMMUNITY: ORAL VACCINES;86
7.2.1.8.6;SUMMARY;87
7.2.1.8.7;ACKNOWLEDGEMENTS;89
7.2.1.8.8;REFERENCES;89
7.2.1.9;CHAPTER 10. IgA ANTIBODIES TO ORAL AND OCULAR BACTERIA IN HUMAN EXTERNAL SECRETIONS;90
7.2.1.9.1;ABSTRACT;90
7.2.1.9.2;KEYWORDS;90
7.2.1.9.3;INTRODUCTION;90
7.2.1.9.4;EFFECT OF ORAL AND OCULAR BACTERIA AT A MUCOSAL SITE ON THE LEVELS OF SERUM IgG AND SECRETORY IgA ANTIBODIES IN SALIVA, TEAR, AND MILK SAMPLES;91
7.2.1.9.5;INDUCTION OF A SECRETORY IgA ANTIBODY RESPONSE FOLLOWING ORAL ADMINISTRATION OF INDIGENOUS S. MUTANS WHOLE CELLS;92
7.2.1.9.6;SUMMARY;93
7.2.1.9.7;ACKNOWLEDGEMENTS;93
7.2.1.9.8;REFERENCES;93
7.2.1.10;CHAPTER 11. THE IgA TYPE PARIETAL CELL ANTIBODY IN GASTRIC JUICE;94
7.2.1.10.1;ABSTRACT;94
7.2.1.10.2;KEYWORDS;94
7.2.1.10.3;INTRODUCTION;94
7.2.1.10.4;MATERIALS AND METHODS;94
7.2.1.10.5;RESULTS;95
7.2.1.10.6;DISCUSSIONS;96
7.2.1.10.7;ACKNOWLEGEMENTS;97
7.2.1.10.8;REFERENCES;97
7.2.1.11;CHAPTER 12. MOLECULAR ANALYSIS OF HUMAN BILE IgA;98
7.2.1.11.1;ABSTRACT;98
7.2.1.11.2;KEYWORDS;98
7.2.1.11.3;INTRODUCTION;98
7.2.1.11.4;MATERIALS AND METHODS;98
7.2.1.11.5;RESULTS;99
7.2.1.11.6;DISCUSSIONS;100
7.2.1.11.7;ACKNOWLEDGEMENTS;101
7.2.1.11.8;REFERENCES;101
7.2.1.12;CHAPTER 13. IgA DIMERS (D), TRIMERS (T) AND TETRAMERS (Q): TRANSFER INTO RAT BILE AND REACTION WITH SECRETORY COMPONENT (SC);102
7.2.1.12.1;ABSTRACT;102
7.2.1.12.2;KEYWORDS;102
7.2.1.12.3;INTRODUCTION;102
7.2.1.12.4;MATERIAL AND METHODS;102
7.2.1.12.5;RESULTS;102
7.2.1.12.6;DISCUSSION;104
7.2.1.12.7;ACKNOWLEDGEMENTS;105
7.2.1.12.8;REFERENCES;105
7.2.1.13;CHAPTER 14. PATHWAYS OF POLYMERIC IgA, SECRETORY COMPONENT AND GALACTOSE-EXPOSING PROTEINS DURING RECEPTOR-MEDIATED ENDOCYTOSIS IN RAT HEPATOCYTES: ULTRASTRUCTURAL DEMONSTRATION AND REQUIREMENTS FOR INTRACELLULAR LIGAND SORTING;106
7.2.1.13.1;ABSTRACT;106
7.2.1.13.2;KEYWORDS;106
7.2.1.13.3;INTRODUCTION;106
7.2.1.13.4;MATERIALS AND METHODS;107
7.2.1.13.5;RESULTS;107
7.2.1.13.6;DISCUSSION;109
7.2.1.13.7;REFERENCES;109
7.2.1.13.8;ACKNOWLEDGEMENTS;109
7.2.1.14;CHAPTER 15. HEPATIC UPTAKE OF HUMAN SECRETORY IgA IN MICE;110
7.2.1.14.1;ABSTRACT;110
7.2.1.14.2;KEY WORDS;110
7.2.1.14.3;INTRODUCTION;110
7.2.1.14.4;MATERIALS AND METHODS;110
7.2.1.14.5;RESULTS;111
7.2.1.14.6;DISCUSSION;113
7.2.1.14.7;ACKNOWLEDGEMENT;113
7.2.1.14.8;REFERENCES;113
7.2.1.15;CHAPTER 16. SECRETORY IgAj AND IgA2 RESPONSES TO ENVIRONMENTAL ANTIGENS;114
7.2.1.15.1;ABSTRACT;114
7.2.1.15.2;KEY WORDS;114
7.2.1.15.3;INTRODUCTION;114
7.2.1.15.4;METHODS;114
7.2.1.15.5;RESULTS;115
7.2.1.15.6;DISCUSSION;116
7.2.1.15.7;ACKNOWLEDGEMENT;117
7.2.1.15.8;REFERENCES;117
7.2.1.16;CHAPTER 17. IgA IN THE BILE, SALVIVA AND URINE OF RATS;118
7.2.1.16.1;ABSTRACT;118
7.2.1.16.2;KEYWORDS;118
7.2.1.16.3;INTRODUCTION;118
7.2.1.16.4;MATERIALS AND METHODS;119
7.2.1.16.5;RESULTS AND DISCUSSION;120
7.2.1.16.6;ACKNOWLEDGEMENTS;121
7.2.1.16.7;REFERENCES;121
7.2.1.17;CHAPTER 18. CHANGES IN SIZE, SUBCLASS AND SC CONTENT OF SERUM IMMUNOGLOBULIN A IN DISEASES WITH HIGH POLYCLONAL IgA;122
7.2.1.17.1;ABSTRACT;122
7.2.1.17.2;KEYWORDS;122
7.2.1.17.3;INTRODUCTION;122
7.2.1.17.4;MATERIAL AND METHODS;122
7.2.1.17.5;RESULTS;123
7.2.1.17.6;DISCUSSION;125
7.2.1.17.7;REFERENCES;125
7.2.1.18;CHAPTER 19. ORIGIN OF IgA IN TEARS OF RATS;126
7.2.1.18.1;INTRODUCTION;126
7.2.1.18.2;MATERIALS AND METHODS;126
7.2.1.18.3;RESULTS;126
7.2.1.18.4;DISCUSSION;127
7.2.1.18.5;REFERENCES;128
7.2.1.19;CHAPTER 20. ANDROGEN REGULATION OF IgA LEVELS IN TEARS OF RATS;130
7.2.1.19.1;INTRODUCTION;130
7.2.1.19.2;MATERIALS AND METHODS;130
7.2.1.19.3;RESULTS;130
7.2.1.19.4;DISCUSSION;131
7.2.1.19.5;REFERENCES;131
7.2.1.20;CHAPTER 21. SECRETORY COMPONENT AND IgA IN THE UTERUS OF THE PREGNANT RAT;132
7.2.1.20.1;ABSTRACT;132
7.2.1.20.2;KEY WORDS;132
7.2.1.20.3;INTRODUCTION;132
7.2.1.20.4;MATERIALS AND METHODS;132
7.2.1.20.5;RESULTS;133
7.2.1.20.6;DISCUSSION;133
7.2.1.20.7;ACKNOWLEDGEMENTS;134
7.2.1.20.8;REFERENCES;134
7.2.1.21;CHAPTER 22. HOMOGENEOUS Ig COMPONENTS IN SERUM AND SECRETIONS OF AGING C57BLIKaLwRij MICE;136
7.2.1.21.1;ABSTRACT;136
7.2.1.21.2;KEYWORDS;136
7.2.1.21.3;INTRODUCTION;136
7.2.1.21.4;MATERIALS AND METHODS;137
7.2.1.21.5;RESULTS;137
7.2.1.21.6;DISCUSSION;138
7.2.1.21.7;ACKNOWLEDGEMENTS;139
7.2.1.21.8;REFERENCES;139
7.2.1.22;CHAPTER 23. THE WASTED MUTANT MOUSE: A MODEL FOR THE STUDY OF IgA DEFICIENCY IN ATAXIATELANGIECTASIA;140
7.2.1.22.1;ABSTRACT;140
7.2.1.22.2;KEYWORDS;140
7.2.1.22.3;INTRODUCTION;140
7.2.1.22.4;EXPERIMENTAL MODEL;140
7.2.1.22.5;RESULTS;140
7.2.1.22.6;ACKNOWLEDGEMENT;143
7.2.1.22.7;REFERENCES;143
7.2.2;A.2. Enzymes;144
7.2.2.1;CHAPTER 24. THE PEROXIDASE SYSTEM IN HUMAN TEARS;144
7.2.2.1.1;ABSTRACT;144
7.2.2.1.2;KEYWORDS;144
7.2.2.1.3;INTRODUCTION;144
7.2.2.1.4;MATERIAL AND METHODS;144
7.2.2.1.5;RESULTS;145
7.2.2.1.6;DISCUSSION;147
7.2.2.1.7;ACKNOWLEDGEMENTS;147
7.2.2.1.8;REFERENCES;147
7.2.2.2;CHAPTER 25. THE BIOLOGICAL SIGNIFICANCE OF LACTOPEROXIDASE IN MILK;148
7.2.2.2.1;ABSTRACT;148
7.2.2.2.2;KEYWORDS;148
7.2.2.2.3;INTRODUCTION;148
7.2.2.2.4;GRAM-POSITIVE ORGANISMS;148
7.2.2.2.5;GRAM-NEGATIVE ORGANISMS;149
7.2.2.2.6;ACTIVATION OF THE LACTOPEROXIDASE SYSTEM;149
7.2.2.2.7;IN VIVO ACTIVITY OF THE LACTOPEROXIDASE SYSTEM;150
7.2.2.2.8;REFERENCES;150
7.2.2.3;CHAPTER 26. CHARACTERIZATION OF LACTOTRANSFERRIN COMPLEXES IN HUMAN MILK;152
7.2.2.3.1;ABSTRACT;152
7.2.2.3.2;KEY WORDS;152
7.2.2.3.3;INTRODUCTION;152
7.2.2.3.4;MATERIALS AND METHODS;152
7.2.2.3.5;RESULTS;152
7.2.2.3.6;CONCLUSION;155
7.2.2.3.7;ACKNOWLEDGMENT;155
7.2.2.3.8;REFERENCES;155
7.2.2.4;CHAPTER 27. BIOCHEMICAL AND IMMUNOLOGICAL PROPERTIES OF PEROXIDASE FROM HUMAN PAROTID SALIVA;156
7.2.2.4.1;ABSTRACT;156
7.2.2.4.2;KEYWORDS;156
7.2.2.4.3;INTRODUCTION;156
7.2.2.4.4;EXPERIMENTAL PROCEDURES;156
7.2.2.4.5;RESULTS;158
7.2.2.4.6;DISCUSSION;160
7.2.2.4.7;ACKNOWLEDGEMENTS;161
7.2.2.4.8;REFERENCES;161
7.2.2.5;CHAPTER 28. SOME STRUCTURAL AND FUNCTIONAL PROPERTIES OF LACTOPEROXIDASE;162
7.2.2.5.1;ABSTRACT;162
7.2.2.5.2;KEYWORDS;162
7.2.2.5.3;INTRODUCTION;162
7.2.2.5.4;RESULTS AND DISCUSSION;162
7.2.2.5.5;ACKNOWLEDGEMENT;163
7.2.2.5.6;REFERENCES;163
7.2.2.6;CHAPTER 29. THE THIOCYANATE BINDING TO LA CTOPEROXIDASE;166
7.2.2.6.1;ABSTRACT;166
7.2.2.6.2;KEYWORDS;166
7.2.2.6.3;INTRODUCTION;166
7.2.2.6.4;EXPERIMENTAL;167
7.2.2.6.5;RESULTS;167
7.2.2.6.6;DISCUSSION;169
7.2.2.6.7;ACKNOWLEDGEMENT;169
7.2.2.6.8;REFERENCES;169
7.2.2.7;CHAPTER 30. INTERACTIONS OF SULPHUR IN PROTEINS WITH LACTOPEROXIDASE IN THE ORAL CAVITY;170
7.2.2.7.1;ABSTRACT;170
7.2.2.7.2;KEYWORDS;170
7.2.2.7.3;DISCUSSION;172
7.2.2.7.4;LITERATURE;172
7.2.2.8;CHAPTER 31. ISOLATION OF A SPUTUM CYSTEINE PROTEASE INHIBITOR;174
7.2.2.8.1;ABSTRACT;174
7.2.2.8.2;KEYWORDS;174
7.2.2.8.3;INTRODUCTION;174
7.2.2.8.4;METHODS AND MATERIALS;174
7.2.2.8.5;RESULTS;175
7.2.2.8.6;DISCUSSION;176
7.2.2.8.7;REFERENCES;177
7.2.2.9;CHAPTER 32. PROTEINASES AND PROTEINASE INHIBITORS IN HUMAN ENDOMETRIAL SECRETION;178
7.2.2.9.1;ABSTRACT;178
7.2.2.9.2;KEY WORDS;178
7.2.2.9.3;INTRODUCTION;178
7.2.2.9.4;MATERIAL AND METHODS;179
7.2.2.9.5;RESULTS AND DISCUSSION;179
7.2.2.9.6;ACKNOWLEDGEMENT;181
7.2.2.9.7;REFERENCES;181
7.2.3;A.3. Lactoferrin;182
7.2.3.1;CHAPTER 33. EFFECT OF PROTEOLYSIS ON THE ANTIMICROBIAL AND IRON-BINDING PROPERTIES OF HUMAN AND BOVINE LACTOFERRINS;182
7.2.3.1.1;ABSTRACT;182
7.2.3.1.2;KEYWORDS;182
7.2.3.1.3;INTRODUCTION;182
7.2.3.1.4;MATERIALS AND METHODS;182
7.2.3.1.5;RESULTS;183
7.2.3.1.6;DISCUSSION;185
7.2.3.1.7;ACKNOWLEDGEMENTS;185
7.2.3.1.8;REFERENCES;185
7.2.3.2;CHAPTER 34. LACTOFERRIN AS COMPLEMENT INHIBITOR IN SYNOVIAL FLUID;186
7.2.3.2.1;ABSTRACT;186
7.2.3.2.2;KEYWORDS;186
7.2.3.2.3;INTRODUCTION;186
7.2.3.2.4;PATIENTS AND METHODS;186
7.2.3.2.5;RESULTS;188
7.2.3.2.6;DISCUSSION;188
7.2.3.2.7;ACKNOWLEDGEMENT;188
7.2.3.2.8;REFERENCES;188
7.2.3.3;CHAPTER 35. EFFECT OF ENTEROCHELIN AND pH ON UPTAKE OF IRON FROM LACTOFERRIN BY ESCHERICHIA COLI;190
7.2.3.3.1;ABSTRACT;190
7.2.3.3.2;KEYWORDS;190
7.2.3.3.3;INTRODUCTION;190
7.2.3.3.4;MATERIALS AND METHODS;190
7.2.3.3.5;RESULTS;191
7.2.3.3.6;DISCUSSION;192
7.2.3.3.7;REFERENCES;192
7.2.3.4;CHAPTER 36. LACTOFERRIN AND FIBRONECTIN IN TEARS OF PATIENTS UNDERGOING CATARACT SURGERY;194
7.2.3.4.1;ABSTRACT;194
7.2.3.4.2;KEYWORDS;194
7.2.3.4.3;INTRODUCTION;194
7.2.3.4.4;MATERIAL AND METHODS;195
7.2.3.4.5;RESULTS AND DISCUSSION;195
7.2.3.4.6;ACKNOWLEDGEMENT;197
7.2.3.4.7;REFERENCES;197
7.2.4;A.4. C.S.F.;198
7.2.4.1;CHAPTER 37. THE SCIENCE OF INTRA-BLOOD-BRAINBARRIER IgG SYNTHESIS;198
7.2.4.1.1;ABSTRACT;198
7.2.4.1.2;KEYWORDS;198
7.2.4.1.3;INTRODUCTION;198
7.2.4.1.4;QUANTITATIVE CSF ANALYSIS;198
7.2.4.1.5;QUALITATIVE ELECTROPHORETIC ANALYSIS OF CSF;200
7.2.4.1.6;REFERENCES;200
7.2.4.2;CHAPTER 38. CEREBROSPINAL FLUID IgG AND Ô CELL SUBPOPULATIONS IN MULTIPLE SCLEROSIS;202
7.2.4.2.1;ABSTRACT;202
7.2.4.2.2;KEYWORDS;202
7.2.4.2.3;INTRODUCTION;202
7.2.4.2.4;MATERIALS AND METHODS;202
7.2.4.2.5;RESULTS;203
7.2.4.2.6;DISCUSSION;206
7.2.4.2.7;ACKNOWLEDGEMENTS;207
7.2.4.2.8;REFERENCES;207
7.2.4.3;CHAPTER 39. DETECTION OF OLIGOCLONAL IgG IN UN CONCENTRATED CEREBROSPINAL FLUID BY AGAROSE ISOELECTRIC FOCUSING AND DOUBLE ANTIBODY A VIDIN-BIO TIN-PER OXIDASE;208
7.2.4.3.1;ABSTRACT;208
7.2.4.3.2;KEYWORDS;208
7.2.4.3.3;INTRODUCTION;208
7.2.4.3.4;MATERIALS AND METHODS;208
7.2.4.3.5;RESULTS AND DISCUSSION;209
7.2.4.3.6;ACKNOWLEDGEMENT;209
7.2.4.3.7;REFERENCES;209
7.2.4.4;CHAPTER 40. METHIONINE(MET)-ENKEPHALIN AND LEUCINE(LEU)-ENKEPHALIN IN CSF OF CHRONIC SCHIZOPHRENICS: CORRELATION WITH PSYCHOPATHOLOGY;212
7.2.4.4.1;ABSTRACT;212
7.2.4.4.2;KEYWORDS;212
7.2.4.4.3;INTRODUCTION;212
7.2.4.4.4;PATIENTS;212
7.2.4.4.5;METHODS;212
7.2.4.4.6;RESULTS;213
7.2.4.4.7;DISCUSSION;214
7.2.4.4.8;ACKNOWLEDGEMENT;215
7.2.4.4.9;REFERENCES;215
7.2.4.5;CHAPTER 44. INFLAMMATORY AND IMMUNE REACTIONS IN THE CSF OF PATIENTS WITH HERPETIC ENCEPHALITIS;216
7.2.4.5.1;ABSTRACT;216
7.2.4.5.2;KEYWORDS;216
7.2.4.5.3;INTRODUCTION;216
7.2.4.5.4;PATIENTS;216
7.2.4.5.5;MATERIAL AND METHODS;217
7.2.4.5.6;RESULTS;217
7.2.4.5.7;DISCUSSION;218
7.2.4.5.8;ACKNOWLEDGEMENTS;219
7.2.4.5.9;REFERENCES;219
7.2.4.6;CHAPTER 45. VARICELLA ZOSTER VIRUS IgG ANTIBODIES PRODUCED BY CSF LYMPHOCYTES IN HERPES ZOSTER;220
7.2.4.6.1;ABSTRACT;220
7.2.4.6.2;KEYWORDS;220
7.2.4.6.3;INTRODUCTION;220
7.2.4.6.4;MATERIAL AND METHODS;220
7.2.4.6.5;RESULTS;221
7.2.4.6.6;CONCLUSIONS;222
7.2.4.6.7;ACKNOWLEDGEMENT;222
7.2.4.6.8;REFERENCES;222
7.2.4.7;CHAPTER 46. THE USE OF INTRATHECAL IgG SYNTHETIC RATES IN DIAGNOSIS;224
7.2.4.7.1;ABSTRACT;224
7.2.4.7.2;KEYWORDS;224
7.2.4.7.3;INTRODUCTION;224
7.2.4.7.4;MATERIAL AND METHODS;224
7.2.4.7.5;RESULTS;225
7.2.4.7.6;DISCUSSION;226
7.2.4.7.7;ACKNOWLEDGEMENTS;227
7.2.4.7.8;REFERENCES;227
7.2.4.8;CHAPTER 47. INTRATHECAL CSF RIBONUCLEASE IN NEUROLOGICAL DISEASES;228
7.2.4.8.1;ABSTRACT;228
7.2.4.8.2;INTRODUCTION;228
7.2.4.8.3;PATIENTS AND METHODS;228
7.2.4.8.4;RESULTS;229
7.2.4.8.5;COMMENTS;230
7.2.4.8.6;REFERENCES;230
7.2.4.9;CHAPTER 48. SEMEIOLOGY OF THE GAMMA GL OB U LIN IC PATTERN OF CEREBROSPINAL FLUID IN CHILDREN;232
7.2.4.9.1;ABSTRACT;232
7.2.4.9.2;KEY WORDS;232
7.2.4.9.3;INTRODUCTION;232
7.2.4.9.4;MATERIAL AND METHODS;232
7.2.4.9.5;RESULTS AND DISCUSSION;233
7.2.4.9.6;REFERENCES;235
7.2.4.10;CHAPTER 49. IgG PRODUCTION WITHIN THE CENTRAL NERVOUS SYSTEM „ A CRITICAL REVIEW OF PROPOSED FORMULAE;236
7.2.4.10.1;ABSTRACT;236
7.2.4.10.2;KEYWORDS;236
7.2.4.10.3;INTRODUCTION;236
7.2.4.10.4;FORMULAE DESIGNED FOR THE QUANTITATIVE DETERMINATION OF INTRATHECAL IgG SYNTHESIS.;236
7.2.4.10.5;RESULTS AND DISCUSSION;237
7.2.4.10.6;CONCLUSIONS;239
7.2.4.10.7;REFERENCES;239
7.2.4.11;CHAPTER 50. IgG SUBCLASSES IN SERUM AND SPINAL FLUID FROM PATIENTS WITH VARIOUS NEUROLOGICAL DISEASES;240
7.2.4.11.1;ABSTRACT;240
7.2.4.11.2;KEYWORDS;240
7.2.4.11.3;INTRODUCTION;240
7.2.4.11.4;MATERIALS AND METHODS;240
7.2.4.11.5;RESULTS AND DISCUSSION;240
7.2.4.11.6;ACKNOWLEDGEMENT;242
7.2.4.11.7;REFERENCES;242
7.2.4.12;CHAPTER 51. A PARAPROTEIN IgA1 OCCURRING IN SERUM, URINE AND CSF: IMMUNOCHEMICAL IDIOTYPIC EVIDENCE OF SYNTHESIS IN SITU OF THE CNS;244
7.2.4.12.1;ABSTRACTS;244
7.2.4.12.2;INTRODUCTION;244
7.2.4.12.3;MATERIAL;244
7.2.4.12.4;RESULTS;245
7.2.4.12.5;CONCLUSION;247
7.2.4.12.6;REFERENCES;247
7.2.4.13;CHAPTER 52. CHROMATOFOCUSING OF CEREBROSPINAL FLUID AND SERUM IMMUNOGLOBULIN G;248
7.2.4.13.1;ABSTRACT;248
7.2.4.13.2;KEYWORDS;248
7.2.4.13.3;INTRODUCTION;248
7.2.4.13.4;MATERIALS AND METHODS;248
7.2.4.13.5;RESULTS AND DISCUSSION;249
7.2.4.13.6;ACKNOWLEDGEMENT;251
7.2.4.13.7;REFERENCES;251
7.2.4.14;CHAPTER 53. FREE LIGHT CHAINS IN MULTIPLE SCLEROSIS;252
7.2.4.14.1;ABSTRACT;252
7.2.4.14.2;KEYWORDS;252
7.2.4.14.3;INTRODUCTION;252
7.2.4.14.4;METHODS;252
7.2.4.14.5;RESULTS/DISCUSSION;253
7.2.4.14.6;REFERENCES;253
7.2.4.15;CHAPTER 54. HETEROGENOUS OLIGOCLONAL PATTERN OF CSF IMMUNOGLOBULINS ANALYSED BY ISOELECTROFOCUSING ON POLYACRYLAMIDE GELS: DUE TO DIFFERENT OLIGOSACCHARIDE CONTENT?;254
7.2.4.15.1;ABSTRACT;254
7.2.4.15.2;KEYWORDS;254
7.2.4.15.3;INTRODUCTION;254
7.2.4.15.4;MATERIAL and METHODS;254
7.2.4.15.5;RESULTS and DISCUSSION;254
7.2.4.15.6;ACKNOWLEDGEMENTS;255
7.2.4.15.7;REFERENCES;255
7.2.4.16;CHAPTER 55. DIFFERENT DISTRIBUTION PATTERN OF RETINOL-BINDING PROTEIN (RBP) AND PREALBUMIN IN CEREBROSPINAL FLUID (CSF) AND BLOOD SERUM;256
7.2.4.16.1;ABSTRACT;256
7.2.4.16.2;KEYWORDS;256
7.2.4.16.3;INTRODUCTION;256
7.2.4.16.4;MATERIAL and METHODS;256
7.2.4.16.5;RESULTS and DISCUSSION;257
7.2.4.16.6;ACKNOWLEDGEMENT;257
7.2.4.16.7;REFERENCES;257
7.2.4.17;CHAPTER 56. DETERMINATION OF C-REACTIVE PROTEIN (CRP) IN CSF BY ENZYME MULTIP LIED IMMUNO-ASSAY TECHNIQUE (EMIT) AND IMMUNONEPHELOMETRY: CORRELATION OF BOTH METHODS;258
7.2.4.17.1;ABSTRACT;258
7.2.4.17.2;KEYWORDS;258
7.2.4.17.3;INTRODUCTION;258
7.2.4.17.4;MATERIAL and METHODS;258
7.2.4.17.5;RESULTS and DISCUSSION;259
7.2.4.17.6;ACKNOWLEDGEMENT;259
7.2.4.17.7;REFERENCES;259
7.2.5;A.5. Colostrum & Milk;260
7.2.5.1;CHAPTER 57. ELECTRON MICROSCOPIC STUDY OF HUMAN COLOSTRAL CELLS;260
7.2.5.1.1;ABSTRACT;260
7.2.5.1.2;KEY WORDS;260
7.2.5.1.3;INTRODUCTION;260
7.2.5.1.4;MATERIALS AND METHODS;261
7.2.5.1.5;RESULTS AND DISCUSSION;261
7.2.5.1.6;REFERENCES;262
7.2.5.2;CHAPTER 58. PRESENCE OF ANTIBODIES TO FOOD ANTIGENS IN HUMAN COLOSTRAL CELLS;264
7.2.5.2.1;ABSTRACT;264
7.2.5.2.2;KEY WORDS;264
7.2.5.2.3;INTRODUCTION;264
7.2.5.2.4;MATERIALS AND METHODS;265
7.2.5.2.5;RESULTS AND DISCUSSION;265
7.2.5.2.6;REFERENCES;266
7.2.5.3;CHAPTER 59. THE IDENTIFICATION OF A HUMAN MILK GANGLIOSIDE WHICH INHIBITS E.COLI AND V.CHOLERAE ENTEROTOXINS;268
7.2.5.3.1;ABSTRACT;268
7.2.5.3.2;KEY WORDS;268
7.2.5.3.3;INTRODUCTION;268
7.2.5.3.4;METHODS AND MATERIALS;268
7.2.5.3.5;RESULTS AND DISCUSSION;269
7.2.5.3.6;ACKNOWLEDGEMENT;271
7.2.5.3.7;REFERENCES;271
7.2.5.4;CHAPTER 60. DOES HUMAN MILK CONTAIN ÂOMBESIN-LIKE MATERIAL?;272
7.2.5.4.1;ABSTRACT;272
7.2.5.4.2;KEYWORDS;272
7.2.5.4.3;INTRODUCTION;272
7.2.5.4.4;METHODS;272
7.2.5.4.5;RESULTS AND DISCUSSION;273
7.2.5.4.6;ACKNOWLEDGEMENTS;274
7.2.5.4.7;REFERENCES;275
7.2.5.5;CHAPTER 61. REACTIONS OF MONOCLONAL ANTIBODIES AGAINST MEMBRANES OF HUMAN MILKFAT GLOBULES WITH UTERINE AND CERVICAL EPITHELIA DURING PROLIFERATIVE AND SECRETORY STAGES;276
7.2.5.5.1;ABSTRACT;276
7.2.5.5.2;KEYWORDS;276
7.2.5.5.3;INTRODUCTION;276
7.2.5.5.4;MATERIALS AND METHODS;277
7.2.5.5.5;RESULTS;277
7.2.5.5.6;DISCUSSION;279
7.2.5.5.7;ACKNOWLEDGMENT;279
7.2.5.5.8;REFERENCES;279
7.2.6;A.6. Female genital secretions;280
7.2.6.1;CHAPTER 62. ANTIBODIES, IMMUNOGLOBULINS AND COMPLEMENT IN OVIDUCT AL FLUID OF RHESUS MONKEYS;280
7.2.6.1.1;ABSTRACT;280
7.2.6.1.2;KEYWORDS;280
7.2.6.1.3;INTRODUCTION;280
7.2.6.1.4;MATERIALS AND METHODS;280
7.2.6.1.5;RESULTS AND COMMENTS;281
7.2.6.1.6;REFERENCES;283
7.2.6.2;CHAPTER 63. IMMUNOLOCALIZATION OF SECRETORY COMPONENT IN NORMAL AND PATHOLOGICAL UTERINE MUCOSA;284
7.2.6.2.1;Abstract;284
7.2.6.2.2;Key words:;284
7.2.6.2.3;Introduction.;284
7.2.6.2.4;Material and Methods;285
7.2.6.2.5;Results;285
7.2.6.2.6;Discussion;285
7.2.6.2.7;References;286
7.2.6.3;CHAPTER 64. THE PROTEIN COMPOSITION OF THE PERITONEAL FLUID DURING THE MENSTRUAL CYCLE;288
7.2.6.3.1;Introduction;288
7.2.6.3.2;Materials and methods;288
7.2.6.3.3;Results;289
7.2.6.3.4;Conclusions;291
7.2.6.3.5;REFERENCES;291
7.2.6.4;CHAPTER 65. RAPID EFFECT OF OVARIAN HORMONES ON SECRETORY COMPONENT (SC) IN UTERINE SECRETIONS OF THE RAT: THE INVOLVEMENT OF RNA SYNTHESIS IN SC PRODUCTION;292
7.2.6.4.1;ABSTRACT;292
7.2.6.4.2;KEYWORDS;292
7.2.6.4.3;INTRODUCTION;292
7.2.6.4.4;MATERIALS AND METHODS;292
7.2.6.4.5;RESULTS;293
7.2.6.4.6;DISCUSSION;293
7.2.6.4.7;ACKNOWLEDGEMENTS;294
7.2.6.4.8;REFERENCES;294
7.2.6.5;CHAPTER 66. PREGNANCY ASSOCIATED PLASMA PROTEIN-A IN HUMAN OVARIAN FOLLICULAR FLUID;296
7.2.6.5.1;ABSTRACT;296
7.2.6.5.2;KEYWORDS;296
7.2.6.5.3;INTRODUCTION;296
7.2.6.5.4;MATERIALS AND METHODS;296
7.2.6.5.5;RESULTS;296
7.2.6.5.6;DISCUSSION;298
7.2.6.5.7;ACKNOWLEDGEMENTS;299
7.2.6.5.8;REFERENCES;299
7.2.6.6;CHAPTER 67. PLACENTAL PROTEIN 5 IN HUMAN OVARIAN FOLLICULAR FLUID;300
7.2.6.6.1;ABSTRACT;300
7.2.6.6.2;KEYWORDS;300
7.2.6.6.3;INTRODUCTION;300
7.2.6.6.4;MATERIALS AND METHODS;300
7.2.6.6.5;RESULTS AND DISCUSSION;300
7.2.6.6.6;ACKNOWLEDGEMENTS;301
7.2.6.6.7;REFERENCES;302
7.2.7;A.7. Male sexual secretions;304
7.2.7.1;CHAPTER 68. ASSESSMENT OF ANTISPERM ANTIBODIES IN NORMAL AND IMMUNIZED MICE;304
7.2.7.1.1;ABSTRACT;304
7.2.7.1.2;KEYWORDS;304
7.2.7.1.3;INTRODUCTION;304
7.2.7.1.4;MATERIALS AND METHODS;304
7.2.7.1.5;RESULTS;305
7.2.7.1.6;DISCUSSION;307
7.2.7.1.7;REFERENCES;307
7.2.7.2;CHAPTER 69. MALE ACCESSORY SEXUAL GLANDS SECRETIONS AND THEIR ANTITHETICAL ROLE IN IMMUNOSURVEILLANCE;308
7.2.7.2.1;ABSTRACT;308
7.2.7.2.2;KEYWORDS;308
7.2.7.2.3;INTRODUCTION;308
7.2.7.2.4;BACKGROUND;309
7.2.7.2.5;IMPLICATIONS;311
7.2.7.2.6;RATIONALE;311
7.2.7.2.7;REFERENCES;313
7.2.7.3;CHAPTER 70. ROLE FOR BETA 2 MICROGLOBULIN IN SPECIATION;314
7.2.7.3.1;ABSTRACT;314
7.2.7.3.2;KEYWORDS;314
7.2.7.3.3;INTRODUCTION;314
7.2.7.3.4;EXPERIMENTAL AND RESULTS;314
7.2.7.3.5;DISCUSSION;316
7.2.7.3.6;REFERENCES;317
7.2.7.4;CHAPTER 71. IMMUNOLOGICAL IDENTIFICATION OF SEMINALPLA S M IN IN TISSUE EXTRACTS OF SEX GLANDS OF BULL;318
7.2.7.4.1;ABSTRACT;318
7.2.7.4.2;KEYWORDS;318
7.2.7.4.3;INTRODUCTION;318
7.2.7.4.4;MATERIAL AND METHODS;319
7.2.7.4.5;RESULTS;319
7.2.7.4.6;DISCUSSION;321
7.2.7.4.7;REFERENCES;321
7.2.7.5;CHAPTER 72. CHARACTERIZATION OF ANGIOTENSIN CONVERTING ENZYME IN HUMAN SEMINAL PLASMA°;322
7.2.7.5.1;ABSTRACT;322
7.2.7.5.2;KEYWORDS;322
7.2.7.5.3;INTRODUCTION;322
7.2.7.5.4;MATERIAL AND METHODS;322
7.2.7.5.5;RESULTS;323
7.2.7.5.6;DISCUSSION;324
7.2.7.5.7;REFERENCES;325
7.2.7.5.8;ACKNOWLEDGEMENT;325
7.2.7.6;CHAPTER 73. PREGNANCY ASSOCIATED PLASMA PROTEIN-Á IN HUMAN SEMINAL PLASMA;326
7.2.7.6.1;ABSTRACT;326
7.2.7.6.2;KEYWORDS;326
7.2.7.6.3;INTRODUCTION;326
7.2.7.6.4;MATERIALS AND METHODS;326
7.2.7.6.5;RESULTS;327
7.2.7.6.6;DISCUSSION;328
7.2.7.6.7;ACKNOWLEDGEMENTS;328
7.2.7.6.8;REFERENCES;328
7.2.7.7;CHAPTER 74. QUANTITATIVE DETERMINATION OF DIFFERENT PROTEINS IN NORMAL AND PATHOLOGICAL SEMEN°;330
7.2.7.7.1;ABSTRACT;330
7.2.7.7.2;KEYWORDS;330
7.2.7.7.3;INTRODUCTION;330
7.2.7.7.4;METHODS;330
7.2.7.7.5;RESULTS AND DISCUSSION;330
7.2.7.7.6;ACKNOWLEDGEMENTS;333
7.2.7.7.7;REFERENCES;333
7.2.7.8;CHAPTER 75. TISSUE KALLIKREIN IN HUMAN SEMINAL FLUID;336
7.2.7.8.1;ABSTRACT;336
7.2.7.8.2;KEYWORDS;336
7.2.7.8.3;INTRODUCTION;336
7.2.7.8.4;METHODS;336
7.2.7.8.5;RESULTS;337
7.2.7.8.6;CONCLUSIONS;339
7.2.7.8.7;ACKNOWLEDGEMENTS;340
7.2.7.8.8;REFERENCES;340
7.2.8;A.8. Saliva;342
7.2.8.1;CHAPTER 76. BLOCKAGE OF SALIVARY MEDIATED AGGLUTINATION BY NON-SPECIFIC AGGREGATED IMMUNOGLOBULINS;342
7.2.8.1.1;ABSTRACT;342
7.2.8.1.2;KEYWORDS;342
7.2.8.1.3;INTRODUCTION;342
7.2.8.1.4;MATERIALS AND METHODS;343
7.2.8.1.5;RESULTS;343
7.2.8.1.6;DISCUSSION;345
7.2.8.1.7;ACKNOWLEDGEMENT;345
7.2.8.1.8;REFERENCES;345
7.2.8.2;CHAPTER 77. ANTI-CANDIDA PROPERTIES OF NATURAL SALIVARY HISTIDINE-RICH AND SYNTHETIC HISTIDINE PEPTIDES: RELEVANCE TO DENTURE STOMATITIS;346
7.2.8.2.1;ABSTRACT;346
7.2.8.2.2;INTRODUCTION;346
7.2.8.2.3;CHEMICAL NATURE OF THE HRP;346
7.2.8.2.4;FUNGISTATIC AND FUNGICIDAL PROPERTIES OF THE HRP;347
7.2.8.2.5;INHIBITION OF GROWTH OF C. ALBICANS ON DENTURE ACRYLIC STRIPS;349
7.2.8.2.6;CONCLUSIONS;350
7.2.8.2.7;ACKNOWLEDGEMENTS;350
7.2.8.2.8;REFERENCES;350
7.2.9;A. 9. Gastro-intestinal;352
7.2.9.1;CHAPTER 78. LOCALIZATION OF CELLS PRODUCING IMMUNOGLOBULINS AND OTHER IMMUNE FACTORS IN HUMAN GASTRIC MUCOSA;352
7.2.9.1.1;ABSTRACT;352
7.2.9.1.2;KEYWORDS;352
7.2.9.1.3;INTRODUCTION;352
7.2.9.1.4;MATERIALS AND METHODS;352
7.2.9.1.5;RESULTS;353
7.2.9.1.6;DISCUSSION;355
7.2.9.1.7;ACKNOWLEDGEMENT;355
7.2.9.1.8;REFERENCES;355
7.2.9.2;CHAPTER 79. PURIFICATION AND CHARACTERIZATION OF GASTRIC MUCUS ANTIGEN (GMA) FROM MUCINOUS OVARIAN CYST FLUID;356
7.2.9.2.1;ABSTRACT;356
7.2.9.2.2;KEYWORDS;356
7.2.9.2.3;INTRODUCTION;356
7.2.9.2.4;MATERIALS AND METHODS;356
7.2.9.2.5;RESULTS AND DISCUSSION;357
7.2.9.2.6;ACKNOWLEDGEMENT;358
7.2.9.2.7;REFERENCES;358
7.2.9.3;CHAPTER 80. IMMUNOHISTOLOGICAL DETECTION OF GASTRIC MUCUS ANTIGEN (GMA) IN HUMAN FETAL AND ADULT TISSUES;360
7.2.9.3.1;ABSTRACT;360
7.2.9.3.2;KEYWORDS;360
7.2.9.3.3;INTRODUCTION;360
7.2.9.3.4;MATERIALS AND METHODS;360
7.2.9.3.5;RESULTS AND DISCUSSION;360
7.2.9.3.6;REFERENCES;361
7.2.9.4;CHAPTER 81. A RAPID AND RELIABLE KINETIC IMMUNONEPHELOMETRIC METHOD (I.N.) FOR ROUTINE ASSAY OF TOTAL IgA IN HUMAN BILE;364
7.2.9.4.1;ABSTRACT;364
7.2.9.4.2;KEYWORDS;364
7.2.9.4.3;INTRODUCTION;364
7.2.9.4.4;MATERIAL AND METHODS;365
7.2.9.4.5;RESULTS;366
7.2.9.4.6;DISCUSSION;367
7.2.9.4.7;ACKNOWLEDGEMENTS;367
7.2.9.4.8;REFERENCES;367
7.2.9.5;CHAPTER 82. IgA ANTI-HAV ANTIBODY IN SERUM FROM PATIENTS WITH HEPATITIS A;368
7.2.9.5.1;ABSTRACT;368
7.2.9.5.2;KEYWORDS;368
7.2.9.5.3;INTRODUCTION;368
7.2.9.5.4;MATERIALS AND METHODS;368
7.2.9.5.5;RESULTS;369
7.2.9.5.6;DISCUSSIONS;370
7.2.9.5.7;REFERENCES;371
7.2.9.6;CHAPTER 83. QUANTITATION OF A NOVEL SERINE PROTEINASE, INGOBSIN BY PRECIPITATION WITH AN ANTIBODY THAT LEAVES ENZYMATIC ACTIVITY INTACT;372
7.2.9.6.1;ABSTRACT;372
7.2.9.6.2;KEYWORDS;372
7.2.9.6.3;INTRODUCTION;372
7.2.9.6.4;MATERIALS AND METHODS;372
7.2.9.6.5;RESULTS;373
7.2.9.6.6;DISCUSSION;373
7.2.9.6.7;ACKNCWLEEGEMEINT;374
7.2.9.6.8;REFERENCES;374
7.2.9.7;CHAPTER 84. MATURATION DEPENDENT CHANGES IN NUCLEOSIDE PHOSPHORYLASE (NP), ADENOSINE DEAMINASE (ADA) AND ADA COMPLEXING PROTEIN (ADCP) IN INTESTINAL EPITHELIAL CELLS;376
7.2.9.7.1;MATERIALS AND METHODS;376
7.2.9.7.2;RESULTS;376
7.2.9.7.3;DISCUSSION;378
7.2.9.7.4;ACKNOWLEDGEMENT;378
7.2.9.7.5;REFERENCES;379
7.2.9.8;CHAPTER 85. PANCREATIC PROTEINS: CHARACTERIZATION OF A COMPONENT DEVOID OF ENZYME ACTIVITY;380
7.2.9.8.1;ABSTRACT;380
7.2.9.8.2;INTRODUCTION;380
7.2.9.8.3;MATERIAL AND METHODS;380
7.2.9.8.4;RESULTS;381
7.2.9.8.5;CONCLUSION;382
7.2.9.8.6;REFERENCES;383
7.2.9.9;CHAPTER 86. EFFECTS OF DIETARY LEGUME PROTEINS ON THE MORPHOLOGY AND SECRETORY RESPONSES OF THE RAT SMALL INTESTINE;384
7.2.9.9.1;ABSTRACT;384
7.2.9.9.2;KEYWORDS;384
7.2.9.9.3;INTRODUCTION;384
7.2.9.9.4;MATERIALS AND METHODS;385
7.2.9.9.5;RESULTS AND DISCUSSION;385
7.2.9.9.6;REFERENCES;387
7.2.9.10;CHAPTER 87. ISOLATION OF A NON-MUCIN MACROGLYCOPROTEIN FROM MECONIUM;388
7.2.9.10.1;ABSTRACT;388
7.2.9.10.2;KEYWORDS;388
7.2.9.10.3;INTRODUCTION;388
7.2.9.10.4;MATERIALS AND METHODS;388
7.2.9.10.5;RESULTS AND DISCUSSION;389
7.2.9.10.6;REFERENCES;391
7.2.9.10.7;ACKNOWLEDGEMENT;391
7.2.9.11;CHAPTER 88. USE OF FECAL ENZYME DETERMINATIONS IN THE DIFFERENTIATION OF MALDIGESTION AND MALABSORPTION IN MAN;392
7.2.9.11.1;ABSTRACT;392
7.2.9.11.2;KEYWORDS;392
7.2.9.11.3;INTRODUCTION;392
7.2.9.11.4;MATERIAL AND METHODS;392
7.2.9.11.5;RESULTS;392
7.2.9.11.6;CONCLUSIONS;393
7.2.9.12;CHAPTER 89. FECAL ENZYME CHANGES IN HUMAN LIVER DISEASES;394
7.2.9.12.1;ABSTRACT;394
7.2.9.12.2;KEYWORDS;394
7.2.9.12.3;INTRODUCTION;394
7.2.9.12.4;MATERIAL AND METHODS;394
7.2.9.12.5;RESULTS;394
7.2.9.12.6;CONCLUSIONS;395
7.2.9.13;CHAPTER 90. PERITONEAL PERMEABILITY FOR SMALL PROTEINS AND IMMUNOGLOBULINS UNDER CARD;396
7.2.9.13.1;ABSTRACT;396
7.2.9.13.2;KEYWORDS;396
7.2.9.13.3;INTRODUCTION;396
7.2.9.13.4;MATERIAL AND METHODS;396
7.2.9.13.5;RESULTS;397
7.2.9.13.6;DISCUSSION;399
7.2.9.13.7;ACKNOWLEDGEMENT;399
7.2.9.13.8;REFERENCES;399
7.2.10;A.10. Nasal;400
7.2.10.1;CHAPTER 91. CELLS PRODUCING IMMUNOGLOBULINS AND OTHER IMMUNE FACTORS IN HUMAN NASAL MUCOSA;400
7.2.10.1.1;ABSTRACT;400
7.2.10.1.2;KEYWORDS;400
7.2.10.1.3;INTRODUCTION;400
7.2.10.1.4;MATERIALS AND METHODS;401
7.2.10.1.5;RESULTS AND DISCUSSION;401
7.2.10.1.6;ACKNOWLEDGEMENTS;403
7.2.10.1.7;REFERENCES;403
7.2.10.2;CHAPTER 92. SECRETORY IgE LEVELS IN RECURRENT NASAL POLYPOSIS;404
7.2.10.2.1;ABSTRACT;404
7.2.10.2.2;KEY WORDS;404
7.2.10.2.3;INTRODUCTION;404
7.2.10.2.4;MATERIAL AND METHODS;404
7.2.10.2.5;RESULTS AND DISCUSSION;406
7.2.10.2.6;ACKNOWLEDGEMENTS;407
7.2.10.2.7;REFERENCES;407
7.2.11;A.11. Broncho-alveolar;408
7.2.11.1;CHAPTER 93. STUDY OF IMMUNOGLOBULINS IN BRONCHOALVEOLAR LAVAGE (BAL);408
7.2.11.1.1;ABSTRACT;408
7.2.11.1.2;KEYWORDS;408
7.2.11.1.3;INTRODUCTION;408
7.2.11.1.4;METHODOLOGY;408
7.2.11.1.5;RESULTS;409
7.2.11.1.6;CONCLUSION;411
7.2.11.1.7;REFERENCES;411
7.2.11.1.8;ACKNOWLEDGMENTS;412
7.2.11.2;CHAPTER 94. SERUM TYPE LEVELS IN III PROCOLLAGEN PEPTIDE CRYPTOGENIC FIBROSING ALVEOLITIS;414
7.2.11.2.1;ABSTRACT;414
7.2.11.2.2;KEYWORDS;414
7.2.11.2.3;INTRODUCTION;414
7.2.11.2.4;METHOD;415
7.2.11.2.5;RESULTS;415
7.2.11.2.6;DISCUSSION;417
7.2.11.2.7;ACKNOWLEDGEMENT;417
7.2.11.2.8;REFERENCES;417
7.2.11.3;CHAPTER ]95. ARE CHANGES IN CHEMOTACTIC ACTIVITY INVOLVED IN ASTHMATIC PROCESSES?;418
7.2.11.3.1;ABSTRACT;418
7.2.11.3.2;KEY WORDS;418
7.2.11.3.3;INTRODUCTION;418
7.2.11.3.4;MATERIAL AND METHOD;418
7.2.11.3.5;RESULTS;419
7.2.11.3.6;DISCUSSION;422
7.2.11.3.7;LITTERATURE;422
7.2.11.4;CHAPTER 96. CIGARETTE SMOKE INDUCED TRACHEAL HYPERSECRETION;424
7.2.11.4.1;ABSTRACT;424
7.2.11.4.2;KEYWORDS;424
7.2.11.4.3;INTRODUCTION;424
7.2.11.4.4;METHODS;424
7.2.11.4.5;RESULTS;425
7.2.11.4.6;DISCUSSION;426
7.2.11.4.7;REFERENCES;427
7.2.12;A.12. Tears;428
7.2.12.1;CHAPTER 97. CELLULAR ORIGIN OF RABBIT AND HUMAN TEAR PROTEINS;428
7.2.12.1.1;ABSTRACT;428
7.2.12.1.2;KEYWORDS;428
7.2.12.1.3;INTRODUCTION;428
7.2.12.1.4;METHODS;428
7.2.12.1.5;RESULTS;429
7.2.12.1.6;SUMMARY;429
7.2.12.1.7;ACKNOWLEDGEMENT;430
7.2.12.1.8;REFERENCES;430
7.2.12.2;CHAPTER 98. COMPARATIVE PROTEIN PATTERNS IN TEARS OF SEVERAL SPECIES;432
7.2.12.2.1;ABSTRACT;432
7.2.12.2.2;KEYWORDS;432
7.2.12.2.3;INTRODUCTION;432
7.2.12.2.4;MATERIALS AND METHODS;432
7.2.12.2.5;RESULTS;432
7.2.12.2.6;DISCUSSION;434
7.2.12.2.7;REFERENCES;434
7.2.12.3;CHAPTER 99. ENZYMOLOGY OF TEAR FLUID;436
7.2.12.3.1;ABSTRACT;436
7.2.12.3.2;KEYWORDS;436
7.2.12.3.3;INTRODUCTION;436
7.2.12.3.4;METHODS;436
7.2.12.3.5;RESULTS;436
7.2.12.3.6;DISCUSSION;438
7.2.12.3.7;REFERENCES;438
7.2.12.4;CHAPTER 100. ESTIMATION OF LYSOZYME BY ENZYME IMMUNOASSAY;440
7.2.12.4.1;ABSTRACT;440
7.2.12.4.2;KEYWORDS;440
7.2.12.4.3;INTRODUCTION;440
7.2.12.4.4;REFERENCES;443
7.2.13;A.13. Synovial;444
7.2.13.1;CHAPTER 101. SYNOVIAL FLUID FIBRONECTIN;444
7.2.13.1.1;ABSTRACT;444
7.2.13.1.2;KEYWORDS;444
7.2.13.1.3;INTRODUCTION;444
7.2.13.1.4;MATERIALS AND METHODS;444
7.2.13.1.5;RESULTS;445
7.2.13.1.6;DISCUSSION;445
7.2.13.1.7;ACKNOWLEDGEMENTS;446
7.2.13.1.8;REFERENCES;446
7.2.13.1.9;FIGURE LEGENDS;446
7.3;SECTION B: Tumor Markers and Targeting (including monoclonals);448
7.3.1;B.1. Immunotoxins;450
7.3.1.1;CHAPTER 102. DRUG Ô ARGETTING FOR 7 NEUROBLASTOMA PATIENTS USING HUMAN POLYCLONAL ANTIBODIES;450
7.3.1.1.1;ABSTRACT;450
7.3.1.1.2;KEYWORDS;450
7.3.1.1.3;INTRODUCTION;450
7.3.1.1.4;ANTIBODY PRODUCTION;450
7.3.1.1.5;CONJUGATION;450
7.3.1.1.6;PATIENTS & PROTOCOL;451
7.3.1.1.7;PRELIMINARY LOCALISATION;451
7.3.1.1.8;DISCUSSION;451
7.3.1.1.9;ACKNOWLEDGMENTS;452
7.3.1.1.10;REFERENCES;452
7.3.1.2;CHAPTER 103. A MODEL FOR CELL KILLING USING RADIOLABELLED ANTIBODIES;454
7.3.1.2.1;ABSTRACT;454
7.3.1.2.2;KEYWORDS;454
7.3.1.2.3;INTRODUCTION;454
7.3.1.2.4;MODEL;454
7.3.1.2.5;RESULTS;455
7.3.1.2.6;DISCUSSION;456
7.3.1.2.7;REFERENCES;457
7.3.1.3;CHAPTER 104. ANTITUMOR EFFECT OF IMMUNOTOXINS IN MOUSE AND HUMAN TUMOR MODELS;458
7.3.1.3.1;ABSTRACT;458
7.3.1.3.2;KEYWORDS;458
7.3.1.3.3;INTRODUCTION;458
7.3.1.3.4;MATERIAL AND METHODS;458
7.3.1.3.5;CONCLUSION;461
7.3.1.3.6;REFERENCES;461
7.3.1.4;CHAPTER 105. BINDING, UPTAKE AND SUBCELLULAR DISTRIBUTION OF TWO MONOCLONAL ANTIBODIES TO HUMAN MILK FAT GLOBULE MEMBRANE STUDIED ON HUMAN MCF 7 BREAST CARCINOMA CELLS;462
7.3.1.4.1;ABSTRACT;462
7.3.1.4.2;KEY WORDS;462
7.3.1.4.3;INTRODUCTION;462
7.3.1.4.4;MATERIAL AND METHODS;463
7.3.1.4.5;RESULTS;463
7.3.1.4.6;DISCUSSION;465
7.3.1.4.7;ACKNOWLEDGEMENT;465
7.3.1.4.8;REFERENCES;465
7.3.1.5;CHAPTER 106. USE OF AN ANTI-TUMOUR MONOCLONAL ANTIBODY FOR TARGETING METHOTREXATE;466
7.3.1.5.1;ABSTRACT;466
7.3.1.5.2;INTRODUCTION;466
7.3.1.5.3;IN VITRO PROPERTIES;466
7.3.1.5.4;IN VIVO THERAPY;467
7.3.1.5.5;DISCUSSION;467
7.3.1.5.6;ACKNOWLEDGEMENTS;468
7.3.1.5.7;REFERENCES;468
7.3.1.6;CHAPTER 107. DAUNORUBICIN CONJUGATED TO GALACTOSYLATED NEOGLYCOPROTEIN AS DRUG CARRIER CONJUGATE FOR HUMAN HEPATOMAS;470
7.3.1.6.1;ABSTRACT;470
7.3.1.6.2;KEY WORDS;470
7.3.1.6.3;INTRODUCTION;470
7.3.1.6.4;MATERIAL AND METHODS;471
7.3.1.6.5;RESULTS;471
7.3.1.6.6;DISCUSSION;473
7.3.1.6.7;ACKOWLEDGEMENT;473
7.3.1.6.8;REFERENCES;473
7.3.1.7;CHAPTER 108. COVALENT LINKAGE OF ANTHRACYCLINES TO MACROMOLECULAR CARRIERS;474
7.3.1.7.1;ABSTRACT;474
7.3.1.7.2;KEY WORDS;474
7.3.1.7.3;INTRODUCTION;474
7.3.1.7.4;MATERIAL AND METHODS;474
7.3.1.7.5;RESULTS;475
7.3.1.7.6;DISCUSSION;477
7.3.1.7.7;ACKNOWLEDGEMENTS;477
7.3.1.7.8;REFERENCES;477
7.3.1.8;CHAPTER 109. TARGETING OF CYTOTOXIC DRUGS BY TRANSFERRIN RECEPTORS; SELECTIVE KILLING OF ACUTE MYELOGENOUS LEUKEMIA CELLS;478
7.3.1.8.1;ABSTRACT;478
7.3.1.8.2;KEYWORDS;478
7.3.1.8.3;INTRODUCTION;478
7.3.1.8.4;MATERIALS & METHODS;478
7.3.1.8.5;RESULTS;479
7.3.1.8.6;DISCUSSION;479
7.3.1.8.7;DISCUS SION (CONTINUED);480
7.3.1.8.8;ACKNOWLEDGEMENTS;481
7.3.1.8.9;REFERENCES;481
7.3.1.9;CHAPTER 110. DRUG TARGETTIN G FOR NEUROBLASTOMA: A CASE REPORT;482
7.3.1.9.1;ABSTRACT;482
7.3.1.9.2;KEYWORDS;482
7.3.1.9.3;INTRODUCTION;482
7.3.1.9.4;CASE HISTORY;482
7.3.1.9.5;CLINICAL RESULTS;483
7.3.1.9.6;DISCUSSION;483
7.3.1.9.7;ACKNOWLEDGMENTS;483
7.3.1.9.8;REFERENCES;483
7.3.1.10;CHAPTER 111. ENHANCEMENT OF THE SPECIFIC CYTOTOXICITY OF ANTICARCINOEMBRYONIC ANTIGEN IMMUNOTOXINS BY ADENOVIRUS AND CARBOXYLIC IONOPHORES;486
7.3.1.10.1;Conclusion;489
7.3.1.10.2;REFERENCES;489
7.3.2;B.2. Tumor imaging;492
7.3.2.1;CHAPTER 112. CHARACTERISTICS OF FIRST AND SECOND ANTIBODIES FOR TUMOUR IMAGING;492
7.3.2.1.1;ABSTRACT;492
7.3.2.1.2;KEYWORDS;492
7.3.2.1.3;INTRODUCTION;492
7.3.2.1.4;MATERIALS AND METHODS;492
7.3.2.1.5;RESULTS;494
7.3.2.1.6;DISCUSSION;494
7.3.2.1.7;ACKNOWLEDGEMENTS;494
7.3.2.1.8;REFERENCES;494
7.3.2.2;CHAPTER 113. OBJECTIVE INTERPRETATION OF ANTIBODY SCANS;496
7.3.2.2.1;ABSTRACT;496
7.3.2.2.2;KEYWORDS;496
7.3.2.2.3;INTRODUCTION;496
7.3.2.2.4;SUBTRACTION AND STATISTICAL THRESHOLDING;496
7.3.2.2.5;DECONVOLUTION AND SHAPE ANALYSIS;497
7.3.2.2.6;CONCLUSIONS;498
7.3.2.2.7;ACKNOWLEDGEMENTS;498
7.3.2.2.8;REFERENCES;498
7.3.2.3;CHAPTER 114. IMMUNOSCINTIGRAPHY WITH 111-INDIUM CONJUGATED MONOCLONAL ANTIBODIES;500
7.3.2.3.1;ABSTRACT;500
7.3.2.3.2;KEY WORDS;500
7.3.2.3.3;INTRODUCTION;500
7.3.2.3.4;MATERIALS AND METHODS;500
7.3.2.3.5;RESULTS;502
7.3.2.3.6;DISCUSSION;504
7.3.2.3.7;REFERENCES;505
7.3.2.4;CHAPTER 115. 111-INDIUM-LABELLED ANTIBODIES FOR TUMOUR DETECTION;506
7.3.2.4.1;ABSTRACT;506
7.3.2.4.2;KEYWORDS;506
7.3.2.4.3;INTRODUCTION;506
7.3.2.4.4;METHODS;507
7.3.2.4.5;PATIENTS;507
7.3.2.4.6;RESULTS;507
7.3.2.4.7;DISCUSSION;508
7.3.2.4.8;ACKNOWLEDGEMENTS;508
7.3.2.4.9;REFERENCES;508
7.3.2.5;CHAPTER 116. PREPARATION OF 111-INDIUM LABELLED ANTIBODIES;510
7.3.2.5.1;ABSTRACT;510
7.3.2.5.2;KEYWORDS;510
7.3.2.5.3;INTRODUCTION;510
7.3.2.5.4;MATERIALS AND METHODS;510
7.3.2.5.5;RESULTS;511
7.3.2.5.6;DISCUSSION;512
7.3.2.5.7;ACKNOWLEDGEMENTS;512
7.3.2.5.8;REFERENCES;512
7.3.2.6;CHAPTER 117. THE LOCALISATION OF AN ANTITUMOUR MONOCLONAL ANTIBODY (791T/36) IN GASTRO-INTESTINAL TUMOURS;514
7.3.2.6.1;ABSTRACT;514
7.3.2.6.2;INTRODUCTION;514
7.3.2.6.3;LOCALISATION OF 791T/36;514
7.3.2.6.4;ACKNOWLEDGEMENTS;515
7.3.2.6.5;REFERENCES;515
7.3.2.7;CHAPTER 118. RADIOIMAGING OF PROSTATIC CARCINOMA WITH PROSTATIC ACID PHOSPHATASE-SPECIFIC POLYCLONAL ANTIBODIES;516
7.3.2.7.1;ABSTRACT;516
7.3.2.7.2;KEYWORDS;516
7.3.2.7.3;INTRODUCTION;516
7.3.2.7.4;PATIENTS;517
7.3.2.7.5;METHODS;517
7.3.2.7.6;RESULTS;517
7.3.2.7.7;DISCUSSION;518
7.3.2.7.8;ACKNOWLEDGEMENTS;518
7.3.2.7.9;REFERENCES;518
7.3.2.8;CHAPTER 119. TISSUE DISTRIBUTION OF RADIOLABELED ANTI-CEA MONOCLONAL ANTIBODIES IN MAN;520
7.3.2.8.1;ABSTRACT;520
7.3.2.8.2;KEYWORDS;520
7.3.2.8.3;INTRODUCTION;520
7.3.2.8.4;MATERIALS AND METHODS;521
7.3.2.8.5;RESULTS;521
7.3.2.8.6;DISCUSSION;523
7.3.2.8.7;REFERENCES;523
7.3.2.9;CHAPTER 120. IMMUNOSCINTIGRAPHY USING F(Ab')2 FRAGMENTS;524
7.3.2.9.1;Antibody Preparation and Labeling;524
7.3.2.9.2;In Vivo Pharmacokinetics and Biodistribution;524
7.3.2.9.3;Imaging and Tumor Localization;525
7.3.2.9.4;References;525
7.3.2.10;CHAPTER 121. STEROID SULPHATASE IMMUNOLOGICALLY DETECTED: A NEW TOOL IN THE HISTOPATHOLOGIC AL INVESTIGATION OF STEROID RELATED HUMAN TUMOURS?;526
7.3.2.10.1;ABSTRACT;526
7.3.2.10.2;KEYWORDS;526
7.3.2.10.3;INTRODUCTION;526
7.3.2.10.4;MATERIALS AND METHODS;526
7.3.3;B.3. Immuno-histochemistry;526
7.3.3.1;CHAPTER 122. STEROID SULPHATASE IMMUNOLOGICALLY DETECTED: A NEW TOOL IN THE HISTOPATHOLOGIC AL INVESTIGATION OF STEROID RELATED HUMAN TUMOURS?;526
7.3.3.1.1;ABSTRACT;526
7.3.3.1.2;KEYWORDS;526
7.3.3.1.3;INTRODUCTION;526
7.3.3.1.4;MATERIALS AND METHODS;526
7.3.3.1.5;RESULTS AND DISCUSSION;527
7.3.3.1.6;REFERENCES;527
7.3.3.2;CHAPTER 123. ANALYSIS OF EWING TUMOUR WITH PANELS OF MONOCLONAL ANTIBODIES;528
7.3.3.2.1;ABSTRACT;528
7.3.3.2.2;KEYWORDS;528
7.3.3.2.3;INTRODUCTION;528
7.3.3.2.4;METHODS;529
7.3.3.2.5;RESULTS;529
7.3.3.2.6;DISCUSSION;530
7.3.3.2.7;ACKNOWLEDGEMENT;531
7.3.3.2.8;REFERENCES;531
7.3.3.3;CHAPTER 124. IMMUNOHIS TOCYTO CHE MICA L ANALYSIS OF GASTROINTESTINAL CARCINOMAS USING IMMUNOPEROXIDASE AND IMMUNOGOLD STAINING WITH MONOCLONAL ANTIBODIES 19.9 AND ANTI CEA;532
7.3.3.3.1;ABSTRACT;532
7.3.3.3.2;KEY WORDS;532
7.3.3.3.3;INTRODUCTION;532
7.3.3.3.4;MATERIAL and METHODS;532
7.3.3.3.5;RESULTS;533
7.3.3.3.6;DISCUSSION;534
7.3.3.3.7;REFERENCES;535
7.3.3.3.8;ACKNOWLEGEMENTS;535
7.3.3.4;CHAPTER 125. TISSUE LOCALISATION OF FOURMONOCLONAL ANTLCEA ANTIBODIES INA COLON TUMOUR XENOGRAFT;536
7.3.3.4.1;ABSTRACT;536
7.3.3.4.2;KEYWORDS;536
7.3.3.4.3;INTRODUCTION;536
7.3.3.4.4;MATERIALS AND METHODS;536
7.3.3.4.5;RESULTS;537
7.3.3.4.6;DISCUSSION;538
7.3.3.4.7;ACKNOWLEDGEMENTS;539
7.3.3.4.8;REFERENCES;539
7.3.3.5;CHAPTER 126. IMMUNOHISTOLOGICALCHARACTERIZATION OF MONOCLONALANTLCEA ANTIBODIES FORRADIOIMMUNOSCINTIGRAPHY ANDIMMUNOTHERAPY;540
7.3.3.5.1;ABSTRACT;540
7.3.3.5.2;KEY WORDS;540
7.3.3.5.3;INTRODUCTION;540
7.3.3.5.4;MATERIAL AND METHODS;540
7.3.3.5.5;RESULTS;541
7.3.3.5.6;DISCUSSION;541
7.3.3.5.7;ACKNOWLEDGMENT;542
7.3.3.5.8;REFERENCES;542
7.3.3.6;CHAPTER 127. IMMUNOCYTOCHEMICAL CHARACTERIZATION OFGASTROINTESTINAL NEOPLASIA BY MONOCLONAL ANTIBODIES;544
7.3.3.6.1;ABSTRACT;544
7.3.3.6.2;KEYWORDS;544
7.3.3.6.3;INTRODUCTION;544
7.3.3.6.4;MATERIAL AND METHODS;544
7.3.3.6.5;RESULTS AND DISCUSSION;545
7.3.3.6.6;ACKNOWLEDGEMENTS;546
7.3.3.6.7;REFERENCES;548
7.3.3.7;CHAPTER 128. ULTRASTRUCTURAL LOCALISATION OFCARCINOEMBRYONIC ANTIGEN (CEA) ONULTRATHIN CRYOSECTIONS OFDIFFERENT TUMOURS;550
7.3.3.7.1;ABSTRACT;550
7.3.3.7.2;KEYWORDS;550
7.3.3.7.3;MATERIALS AND METHODS;550
7.3.3.7.4;RESULTS;550
7.3.3.7.5;LEGENDS TO FIGURES;553
7.3.3.7.6;REFERENCES;553
7.3.3.7.7;ACKNOWLEDGEMENTS;553
7.3.3.8;CHAPTER 129. GENERATION OF MONOCLONALANTIBODIES REACTIVE WITHGLYCOPROTEIN MARKER OF APOCRINEEPITHELIUM AND METASTATIC BREASTCARCINOMA;554
7.3.3.8.1;ABSTRACT;554
7.3.3.8.2;KEYWORDS;554
7.3.3.8.3;INTRODUCTION;554
7.3.3.8.4;MATERIALS AND METHODS;554
7.3.3.8.5;RESULTS;555
7.3.3.8.6;CONCLUSION;557
7.3.3.8.7;REFERENCES;557
7.3.3.9;CHAPTER 130. IDENTIFICATION OF PR Ï LI FE RA TIVEL YACTIVE CELLS BY MONOCLONALANTIBODIES AGAINST DNA - CYTOSINE-5 METHYLTRANSFERASE;558
7.3.3.9.1;ABSTRACT;558
7.3.3.9.2;KEYWORDS;558
7.3.3.9.3;INTRODUCTION;558
7.3.3.9.4;MATERIALS AND METHODS;559
7.3.3.9.5;RESULTS AND DISCUSSION;559
7.3.3.9.6;REFERENCES;561
7.3.3.10;CHAPTER 131. MONOCLONAL ANTIBODIES TOCYTOKERATIN FILAMENTS IN THESTUDY OF TUMOR HISTOGENESIS;562
7.3.3.10.1;ABSTRACT;562
7.3.3.10.2;INTRODUCTION;562
7.3.3.10.3;MATERIALS AND METHODS;562
7.3.3.10.4;RESULTS AND DISCUSSION;563
7.3.3.10.5;ACKNOWLEDGEMENTS;564
7.3.3.10.6;REFERENCES;564
7.3.3.11;CHAPTER 132. MONOCLONAL ANTIBODIES TOCYTOKERATINS IN THE STUDY OFPREMALIGNANT LESIONS OF THEUTERINE CERVIX;566
7.3.3.11.1;ABSTRACT;566
7.3.3.11.2;INTRODUCTION;566
7.3.3.11.3;MATERIALS AND METHODS;567
7.3.3.11.4;RESULTS;567
7.3.3.11.5;DISCUSSION;568
7.3.3.11.6;ACKNOWLEDGEMENTS;569
7.3.3.11.7;REFERENCES;569
7.3.3.12;CHAPTER 133. IMMUNOHISTOCHEMICAL CHARACTERIZATION OF A BIOTINLABELLEDMONOCLONAL ANTIBODY TOCYTOKERATINS;570
7.3.3.12.1;ABSTRACT;570
7.3.3.12.2;KEY WORDS;570
7.3.3.12.3;INTRODUCTION;570
7.3.3.12.4;METHODS;571
7.3.3.12.5;RESULTS;571
7.3.3.12.6;DISCUSSION;572
7.3.3.12.7;REFERENCES;573
7.3.3.13;CHAPTER 134. IMMUNOHISTOLOGICAL STUDIES OFHUMAN SARCOMAS WITH MONOCLONALANTIBODIES;574
7.3.3.13.1;ABSTRACT;574
7.3.3.13.2;KEYWORDS;574
7.3.3.13.3;INTRODUCTION;574
7.3.3.13.4;MATERIAL AND METHODS;574
7.3.3.13.5;RESULTS;575
7.3.3.13.6;DISCUSSION;576
7.3.3.13.7;REFERENCES;576
7.3.3.13.8;ACKNOWLEDGEMENTS;576
7.3.3.14;CHAPTER 135. FLUORESCENT PROBES FOR TUMOURCELLS;578
7.3.3.14.1;ABSTRACT;578
7.3.3.14.2;KEYWORDS;578
7.3.3.14.3;INTRODUCTION;578
7.3.3.14.4;RESULTS AND DISCUSSION;578
7.3.3.14.5;CONCLUSION;580
7.3.3.14.6;REFERENCES;580
7.3.3.15;CHAPTER 136. SPECIFIC IDENTIFICATION OF NORMALAND MALIGNANT HUMAN PROSTATICTISSUES USING MONOCLONALANTIBODIES;582
7.3.3.15.1;ABSTRACT;582
7.3.3.15.2;KEY WORDS;582
7.3.3.15.3;INTRODUCTION;582
7.3.3.15.4;MATERIALS AND METHODS;582
7.3.3.15.5;RESULTS AND DISCUSSION;583
7.3.3.15.6;REFERENCES;584
7.3.3.16;CHAPTER 137. DETECTION WITH A MONOCLONALANTIBODY AN ESTROGEN RECEPTORASSOCIATED ANTIGEN IN MAMMARYAND OVARIAL CARCINOMAS;586
7.3.3.16.1;ABSTRACT;586
7.3.3.16.2;KEYWORDS;586
7.3.3.16.3;INTRODUCTION;586
7.3.3.16.4;MATERIAL AND METHODS;586
7.3.3.16.5;RESULTS;586
7.3.3.16.6;DISCUSSION;588
7.3.3.16.7;ACKNOWLEDGEMENT;589
7.3.3.16.8;REFERENCES;589
7.3.3.17;CHAPTER 138. IMMUNOHISTOCHEMICAL REACTION OFTHREE MONOCLONAL ANTIBODIES TOHUMAN MILK FAT GLOBULE MEMBRANEWITH HUMAN NORMAL AND TUMORALTISSUES;590
7.3.3.17.1;ABSTRACT;590
7.3.3.17.2;KEYWORDS;590
7.3.3.17.3;INTRODUCTION;590
7.3.3.17.4;MATERIAL AND METHODS;591
7.3.3.17.5;RESULTS;591
7.3.3.17.6;DISCUSSION;592
7.3.3.17.7;ACKOWLEDGEMENTS;593
7.3.3.17.8;REFERENCES;593
7.3.3.18;CHAPTER 139. SPECIFIC ENZYME TREATMENT ISREQUIRED FOR INDIVIDUALMONOCLONAL ANTIBODIES INIMMUNOHISTOCHEMISTRY WITHFORMALIN FIXED SECTIONS;594
7.3.3.18.1;INTRODUCTION;594
7.3.3.18.2;METHODS;594
7.3.3.18.3;RESULTS;595
7.3.3.18.4;DISCUSSION;595
7.3.3.18.5;ACKNOWLEDGEMENTS;595
7.3.3.18.6;REFERENCES;596
7.3.3.19;CHAPTER 140. IMMUNOHISTOCHEMICAL LOCALIZATIONOF THE IMMUNODOMINANTDIFFERENTIATION ANTIGEN LACTO-NFUCOPENTAOSEIII IN NORMAL ADULTAND FETAL TISSUES UTILIZINGMONOCLONAL ANTIBODIES;598
7.3.3.19.1;ABSTRACT;598
7.3.3.19.2;KEY WORDS;598
7.3.3.19.3;INTRODUCTION;598
7.3.3.19.4;MATERIALS AND METHODS;598
7.3.3.19.5;RESULTS;599
7.3.3.19.6;DISCUSSION;602
7.3.3.19.7;REFERENCES;603
7.3.3.20;CHAPTER 141. FOETAL PANCREAS ANTIGENS ASPOSSIBLE MARKERS OF PRECANCEROUSSTAGE IN BOP INDUCED PANCREATICCARCINOMA;604
7.3.3.20.1;ABSTRACT;604
7.3.3.20.2;INTRODUCTION;604
7.3.3.20.3;MATERIAL AND METHODS;605
7.3.3.20.4;DISCUSSION;607
7.3.3.20.5;REFERENCES;607
7.3.4;B.4. Receptors;608
7.3.4.1;CHAPTER 142. PREGNANCY PROTEINS IN BREASTCANCER: STUDIES USING TUMOURCYTOSOLS AND THE OESTROGENSENSITIVECELL LINE MCF-7;608
7.3.4.1.1;ABSTRACT;608
7.3.4.1.2;KEYWORDS;608
7.3.4.1.3;PAGINTRODUCTION;608
7.3.4.1.4;MATERIALS AND METHODS;609
7.3.4.1.5;RESULTS;609
7.3.4.1.6;DISCUSSION;610
7.3.4.1.7;ACKNOWLEDGEMENTS;611
7.3.4.1.8;REFERENCES;611
7.3.4.2;CHAPTER 143. EVIDENCE FOR ALPHAFETOPROTEINRECEPTORS IN THE MCF-7 HUMANBREAST CANCER CELL LINE;612
7.3.4.2.1;ABSTRACT;612
7.3.4.2.2;KEYWORDS;612
7.3.4.2.3;INTRODUCTION;612
7.3.4.2.4;MATERIAL AND METHODS;613
7.3.4.2.5;RESULTS;613
7.3.4.2.6;DISCUSSION;615
7.3.4.2.7;ACKNOWLEDGMENT;615
7.3.4.2.8;REFERENCES;615
7.3.4.3;CHAPTER 144. SECRETORY COMPONENT IN BREASTCANCER: CORRELATIONS WITH PATIENTAGE AND HORMONE RECEPTOR LEVELSIN PRIMARY BREAST TUMORS;616
7.3.4.3.1;ABSTRACT;616
7.3.4.3.2;KEYWORDS;616
7.3.4.3.3;INTRODUCTION;616
7.3.4.3.4;MATERIALS AND METHODS;616
7.3.4.3.5;RESULTS;617
7.3.4.3.6;DISCUSSION;618
7.3.4.3.7;ACKNOWLEDGEMENTS;618
7.3.4.3.8;REFERENCES;618
7.3.4.4;CHAPTER 145. TRANSFERRIN RECEPTORS AND TUMORCELL GROWTH;620
7.3.4.4.1;ABSTRACT;620
7.3.4.4.2;KEYWORDS;620
7.3.4.4.3;INTRODUCTION;620
7.3.4.4.4;MATERIALS AND METHODS;621
7.3.4.4.5;RESULTS;621
7.3.4.4.6;DISCUSSION;623
7.3.4.4.7;ACNOWLEDGEMENTS;623
7.3.4.4.8;REFERENCES;623
7.3.4.5;CHAPTER 146. SPECIFIC INTERACTION OF RAT HEPATICASIALOGLYCOPROTEIN RECEPTOR WITHCELL SURFACE MARKERS OF RAT ANDMOUSE TUMOR CELLS;624
7.3.4.5.1;ABSTRACT;624
7.3.4.5.2;KEYWORDS;624
7.3.4.5.3;INTRODUCTION;624
7.3.4.5.4;MATERIAL AND METHODS;624
7.3.4.5.5;RESULTS;625
7.3.4.5.6;DISCUSSION;627
7.3.4.5.7;ACKNOWLEDGEMENT;627
7.3.4.5.8;REFERENCES;627
7.3.4.6;CHAPTER 147. TRANSFERRIN RECEPTORS, HLA-A,B,C,AND AMNION ANTIGENS IN BREASTADENOCARCINOMA;628
7.3.4.6.1;ABSTRACT;628
7.3.4.6.2;KEYWORDS;628
7.3.4.6.3;INTRODUCTION;628
7.3.4.6.4;MATERIALS AND METHODS;628
7.3.4.6.5;RESULTS;629
7.3.4.6.6;DISCUSSION;631
7.3.4.6.7;REFERENCES;631
7.3.4.7;CHAPTER 148. CHARACTERIZATION AND PURIFICATIONOF CYTOSOLIC AND NUCLEARESTROGEN RECEPTORS;632
7.3.4.7.1;ABSTRACT;632
7.3.4.7.2;KEYWORDS;632
7.3.4.7.3;INTRODUCTION;632
7.3.4.7.4;ACKNOWLEDGEMENT;635
7.3.4.7.5;REFERENCES;635
7.3.5;B.5. Tumor markers;636
7.3.5.1;CHAPTER 149. MONITORING OF OVARIAN CARCINOMASWITH CA 12.5 ANTIGEN RADIOIMMUNO-ASSAY;636
7.3.5.2;CHAPTER 150. CANCER ANTIGEN CA 125 IN SERUM OFPATIENTS WITH OVARIAN CANCER;638
7.3.5.2.1;ABSTRACT;638
7.3.5.2.2;KEYWORDS;638
7.3.5.2.3;INTRODUCTION;638
7.3.5.2.4;MATERIAL A N D METHODS;638
7.3.5.2.5;RESULTS;639
7.3.5.2.6;COMMENTS AND CONCLUSIONS;641
7.3.5.2.7;REFERENCES;641
7.3.5.3;CHAPTER 151. CA 125 SERIC LEVELS IN NON OVARIAN PATHOLOGIES;642
7.3.5.3.1;ABSTRACT;642
7.3.5.3.2;INTRODUCTION;642
7.3.5.3.3;MATERIAL AND METHOD;643
7.3.5.3.4;RESULTS;643
7.3.5.3.5;DISCUSSION;643
7.3.5.3.6;CONCLUSIONS;644
7.3.5.3.7;REFERENCES;644
7.3.5.4;CHAPTER 152. THE NEW MONOCLONAL OVARIANCANCER ANTIBODY CA 12-5;646
7.3.5.4.1;ABSTRACT;646
7.3.5.4.2;KEYWORDS;646
7.3.5.4.3;RESULTS;647
7.3.5.4.4;DISCUSSION;649
7.3.5.4.5;REFERENCES;649
7.3.5.5;CHAPTER 153. VALUE OF CA 12.5 ANTIGEN AS TUMOURMARKER: PRELIMINARY RESULTS;650
7.3.5.5.1;MATERIAL AND METHODS;650
7.3.5.5.2;RESULTS;650
7.3.5.5.3;DISCUSSION;652
7.3.5.5.4;REFERENCES;653
7.3.5.6;CHAPTER 154. CLINICAL FOLLOW-UP OF PATIENTSWITH GASTROINTESTINAL CANCERSUSING CA 19-9 AND CEA-TESTS WITHMONOCLONAL ANTIBODIES;654
7.3.5.6.1;ABSTRACT;654
7.3.5.6.2;KEYV70RDS;654
7.3.5.6.3;INTRODUCTION;654
7.3.5.6.4;MATERIALS AND METHODS;655
7.3.5.6.5;RESULTS;655
7.3.5.6.6;DISCUSSION;658
7.3.5.6.7;REFERENCES;658
7.3.5.7;CHAPTER 155. THE VALUE OF CENTOCOR Ca 19-9 ’ ORGASTROINTESTINAL CANCERASSOCIATED ANTIGEN (GICA) IN THEDIAGNOSIS AND PROGNOSIS OFCOLORECTAL CANCER;660
7.3.5.7.1;Abstract;660
7.3.5.7.2;Introduction;660
7.3.5.7.3;Material and Methods;660
7.3.5.7.4;Results;661
7.3.5.7.5;Discussion;663
7.3.5.7.6;References;663
7.3.5.8;CHAPTER 156. VALUE OF CA 19.9 ANTIGEN AS TUMORMARKER: PRELIMINARY RESULTS;664
7.3.5.8.1;MATERIAL AND METHODS;664
7.3.5.8.2;RESULTS;664
7.3.5.8.3;DISCUSSION;666
7.3.5.8.4;ACKNOWLEDGEMENTS;667
7.3.5.8.5;REFERENCES;667
7.3.5.9;CHAPTER 157. A NOVEL 19,000 MEMBRANEGLYCOPROTEIN PURIFED FROM HUMANRED BLOOD CELLS USING AMONOCLONAL ANTIBODY;668
7.3.5.9.1;ABSTRACT;668
7.3.5.9.2;KEYWORDS;668
7.3.5.9.3;INTRODUCTION;668
7.3.5.9.4;MATERIALS AND METHODS;668
7.3.5.9.5;RESULTS;669
7.3.5.9.6;CONCLUSION;671
7.3.5.9.7;ACKNOWLEDGEMENTS;671
7.3.5.9.8;REFERENCES;671
7.3.5.10;CHAPTER 158. B5, A MONOCLONAL ANTIBODYAGAINST A NEW TUMOUR MARKER ONHUMAN ERYTHROCYTES;672
7.3.5.10.1;ABSTRACT;672
7.3.5.10.2;KEYWORDS;672
7.3.5.10.3;INTRODUCTION;672
7.3.5.10.4;ACKNOWLEDGEMENT;674
7.3.5.10.5;REFERENCES;674
7.3.5.11;CHAPTER 159. MACRO-CREATINE KINASE ISOENZYME(MACRO-CK), A MACROMOLECULARFORM OF A TUMOR-ASSOCIATEDMARKER (CK-BB), IN HYPOTHYROIDISM;676
7.3.5.11.1;KEY WORDS;676
7.3.5.11.2;INTRODUCTION;676
7.3.5.11.3;CASE REPORT;676
7.3.5.11.4;DISCUSSION;677
7.3.5.11.5;REFERENCES;679
7.3.5.12;CHAPTER 160. SERUM NEURON-SPECIFIC EN Ï LÄSELEVELS IN LUNG DISEASES: AVALUABLE MARKER FOR SMALL-CELLLUNG CANCER;680
7.3.5.12.1;ABSTRACT;680
7.3.5.12.2;KEYWORDS;680
7.3.5.12.3;INTRODUCTION;680
7.3.5.12.4;MATERIALS AND METHODS;680
7.3.5.12.5;DISTRIBUTION OF PATIENTS AND TESTED SAMPLES;680
7.3.5.12.6;RESULTS AND DISCUSSION;681
7.3.5.12.7;ACKNOWLEDGEMENT;683
7.3.5.12.8;REFERENCES;683
7.3.5.13;CHAPTER 161. COMPLEMENT SPLIT PRODUCT C3d AS ATUMOR MARKER?;684
7.3.5.13.1;ABSTRACT;684
7.3.5.13.2;KEYWORDS;684
7.3.5.13.3;INTRODUCTION;684
7.3.5.13.4;MATERIALS AND METHODS;684
7.3.5.13.5;RESULTS;685
7.3.5.13.6;CONCLUSION;686
7.3.5.13.7;ACKNOWLEDGEMENT;687
7.3.5.13.8;REFERENCES;687
7.3.5.14;CHAPTER 162. A SANDWICH-RADIOIMMUNOASSA Y FORA NEW ANTIGEN (MAM-6) PRESENT INTHE SERA OF PATIENTS WITHMETASTASIZED CARCINOMAS;688
7.3.5.14.1;ABSTRACT;688
7.3.5.14.2;KEYWORDS;688
7.3.5.14.3;INTRODUCTION;688
7.3.5.14.4;MATERIALS AND METHODS;688
7.3.5.14.5;RESULTS;689
7.3.5.14.6;DISCUSSION;690
7.3.5.14.7;ACKNOWLEDGEMENTS;690
7.3.5.14.8;REFERENCES;690
7.3.5.15;CHAPTER 163. FERRITIN: ITS STATUS AS A TUMOUR MARKER;692
7.3.5.15.1;ABSTRACT;692
7.3.5.15.2;KEYWORDS;692
7.3.5.15.3;REFERENCES;694
7.3.5.15.4;ACKNOWLEDGEMENTS;695
7.3.5.16;CHAPTER 164. THE MOLECULAR CHARACTERISTICSAND THE SIGNIFICANCE OF ONCOFETALFERRITIN IN THE DIAGNOSIS OF BREASTCANCER;696
7.3.5.16.1;ABSTRACT;696
7.3.5.16.2;KEYWORDS;696
7.3.5.16.3;INTRODUCTION;696
7.3.5.16.4;EXPERIMENTAL;697
7.3.5.16.5;REFERENCES;700
7.3.5.17;CHAPTER 165. THE USE OF MONOCLONAL ANDPOLYCLONAL ANTIBODIES FOR THEASSAY OF FERRITIN IN MALIGNANTDISEASE;702
7.3.5.17.1;ABSTRACT;702
7.3.5.17.2;KEYWORDS;702
7.3.5.17.3;INTRODUCTION;702
7.3.5.17.4;MATERIAL AND METHODS;702
7.3.5.17.5;RESULTS;703
7.3.5.17.6;DISCUSSION;703
7.3.5.17.7;REFERENCES;704
7.3.5.18;CHAPTER 166. THE SOURCE OF SERUM FERRITIN INPATIENTS WITH MALIGNANT TUMOURS;706
7.3.5.18.1;ABSTRACT;706
7.3.5.18.2;KEYWORDS;706
7.3.5.18.3;INTRODUCTION;706
7.3.5.18.4;MATERIAL AND METHODS;706
7.3.5.18.5;RESULTS;707
7.3.5.18.6;DISCUSSION;707
7.3.5.18.7;REFERENCES;708
7.3.5.19;CHAPTER 167. CLINICALLY SIGNIFICANTCORRELATIONS BETWEEN BLOODTRANSFUSIONS, FERRITIN ANDPROGNOSIS IN NEUROBLASTOMA;710
7.3.5.19.1;ABSTRACT;710
7.3.5.19.2;KEYWORDS;710
7.3.5.19.3;INTRODUCTION;710
7.3.5.19.4;MATERIALS AND METHODS;710
7.3.5.19.5;RESULTS;712
7.3.5.19.6;DISCUSSION;714
7.3.5.19.7;ACKNOWLEDGEMENT;715
7.3.5.19.8;REFERENCES;715
7.3.5.20;CHAPTER 168. THE DISTRIBUTION OF FERRITIN ANDFERRIC IRON IN THE SPLEENS OFLYMPHOMA PATIENTS AND CONTROLS;716
7.3.5.20.1;ABSTRACT;716
7.3.5.20.2;KEYWORDS;716
7.3.5.20.3;INTRODUCTION;716
7.3.5.20.4;MATERIALS AND METHODS;716
7.3.5.20.5;DISCUSSION;717
7.3.5.20.6;REFERENCES;718
7.3.5.21;CHAPTER 169. SERUM FERRITIN IN PATIENTS WITHGYNAECOLOGICAL CANCER;720
7.3.5.21.1;ABSTRACT;720
7.3.5.21.2;KEYWORDS;720
7.3.5.21.3;INTRODUCTION;720
7.3.5.21.4;METHODS;720
7.3.5.21.5;RESULTS AND DISCUSSION;720
7.3.5.21.6;CONCLUSION;723
7.3.5.21.7;REFERENCES;723
7.3.5.22;CHAPTER 170. SERUM LEVELS OF FERRITIN,LACTOFERRIN AND LYSOZYME INPATIENTS WITH DISSEMINATED NONSEMINOMATOUSGERM CELL TUMORSARE INFLUENCED BY CHEMOTHERAPY;724
7.3.5.22.1;ABSTRACT;724
7.3.5.22.2;KEYWORDS;724
7.3.5.22.3;INTRODUCTION;724
7.3.5.22.4;PATIENTS AND METHODS;724
7.3.5.22.5;RESULTS;726
7.3.5.22.6;DISCUSSION;726
7.3.5.22.7;REFERENCES;726
7.3.5.23;CHAPTER 171. CEA: A USEFUL PROGNOSTIC MARKERIN SMALL CELL LUNG CANCER;728
7.3.5.23.1;ABSTRACT;728
7.3.5.23.2;KEY WORDS;728
7.3.5.23.3;INTRODUCTION;728
7.3.5.23.4;MATERIALS AND METHODS;728
7.3.5.23.5;RESULTS;729
7.3.5.23.6;CONCLUSIONS;730
7.3.5.23.7;ACKNOWLEDGEMENT;730
7.3.5.23.8;REFERENCES;730
7.3.5.24;CHAPTER 172. COMPARISON OF POLY- ANDMONOCLONAL ANTIBODIES FORPLASMA DETERMINATION IN NORMALINDIVIDUALS, PATIENTS WITH BENIGNLUNG DISEASES AND PATIENTS WITHLUNG CANCER;732
7.3.5.24.1;ABSTRACT;732
7.3.5.24.2;KEYWORDS;732
7.3.5.24.3;INTRODUCTION;732
7.3.5.24.4;MATERIALS AND METHODS;733
7.3.5.24.5;RESULTS;733
7.3.5.24.6;DISCUSSION;735
7.3.5.24.7;ACKNOWLEDGEMENT;735
7.3.5.24.8;REFERENCES;735
7.3.5.25;CHAPTER 173. DENOCARCINOMA POLYCLONALANTIBODY: AS A DIAGNOSTIC TOOL OFHIGH SPECIFICITY;736
7.3.5.25.1;KEYWORDS;736
7.3.5.25.2;INTRODUCTION;736
7.3.5.25.3;MATERIALS AND METHODS;736
7.3.5.25.4;RESULTS;737
7.3.5.25.5;DISCUSSION;737
7.3.5.25.6;REFERENCES;739
7.3.5.26;CHAPTER 174. ALTERATION OF CIRCADIAN VARIATIONIN SERUM CONCENTRATIONS OFCARCINOEMBRYONIC ANTIGEN (CEA) INCANCER;740
7.3.5.26.1;ABSTRACT;740
7.3.5.26.2;KEYWORDS;740
7.3.5.26.3;INTRODUCTION;740
7.3.5.26.4;MATERIAL AND METHODS;740
7.3.5.26.5;RESULTS;741
7.3.5.26.6;CONCLUSIONS;741
7.3.5.26.7;REFERENCES;742
7.3.5.27;CHAPTER 175. SERUM CEA AND PHI AS TUMORMARKERS IN THE FOLLOW UP OFBREAST CANCER PATIENTS;744
7.3.5.27.1;ABSTRACT;744
7.3.5.27.2;KEYWORDS;744
7.3.5.27.3;INTRODUCTION;744
7.3.5.27.4;PATIENTS AND METHODS;744
7.3.5.27.5;RESULTS;745
7.3.5.27.6;DISCUSSION;747
7.3.5.27.7;REFERENCES;747
7.3.5.28;CHAPTER 176. SIGNIFICANCE OF CEA ANTIBODYAFFINITY FOR RECOGNITION OF CANCERBY PLASMA DETERMINATIONS;748
7.3.5.28.1;ABSTRACT;748
7.3.5.28.2;KEY WORDS;748
7.3.5.28.3;INTRODUCTION;748
7.3.5.28.4;MATERIAL AND METHODS;748
7.3.5.28.5;RESULTS;749
7.3.5.28.6;DISCUSSION;752
7.3.5.28.7;REFERENCES;752
7.3.5.29;CHAPTER 177. WHAT IS TPA?(TISSUE POLYPEPTIDEANTIGEN): ON THE RELATION BETWEENTPA AND CYTOKERATINS;754
7.3.5.29.1;Keywords:;754
7.3.5.29.2;References;754
7.3.5.30;CHAPTER 178. MONOCLONAL ANTI-TP A ANTIBODIESAND THEIR USE FORIMMUNOHISTOCHEMICALDEMONSTRATION OF TPA;756
7.3.5.30.1;ABSTRACT;756
7.3.5.30.2;KEYWORDS;756
7.3.5.30.3;INTRODUCTION;756
7.3.5.30.4;MATERIALS AND METHODS;757
7.3.5.30.5;RESULTS AND DISCUSSION;757
7.3.5.30.6;REFERENCES;759
7.3.5.31;CHAPTER 179. DISPLAY OF TPA IN INTERPHASE ANDMITOSIS;760
7.3.5.31.1;ABSTRACT;760
7.3.5.31.2;KEY WORDS;760
7.3.5.31.3;INTRODUCTION;760
7.3.5.31.4;MATERIALS AND METHODS;760
7.3.5.31.5;RESULTS;762
7.3.5.31.6;DISCUSSION;763
7.3.5.31.7;REFERENCES;763
7.3.5.32;CHAPTER 180. STAINING FOR TPA AND CEA AS AN AIDIN SEARCH FOR PRIMARY TUMORS ANDMICROMETASTASES;764
7.3.5.32.1;ABSTRACT;764
7.3.5.32.2;INTRODUCTION;764
7.3.5.32.3;MATERIALS AND METHODS;764
7.3.5.32.4;RESULTS;764
7.3.5.32.5;DISCUSSION;767
7.3.5.32.6;REFERENCES;767
7.3.5.32.7;ACKNOWLEDGEMENT;767
7.3.5.33;CHAPTER 181. TISSUE POLYPEPTIDE ANTIGEN (TPA) INPATIENTS WITH BREAST CANCER „LONGITUDINAL STUDY;768
7.3.5.33.1;Abstract.;768
7.3.5.33.2;Keywords;768
7.3.5.33.3;Introduction;768
7.3.5.33.4;Materials and Methods;768
7.3.5.33.5;Results;769
7.3.5.33.6;Discussion;770
7.3.5.33.7;Acknowledgement;771
7.3.5.33.8;References;771
7.3.5.34;CHAPTER 182. TISSUE POLYPEPTIDE ANTIGEN (TPA) ASA TUMOUR MARKER IN SMALL CELL(SCLC) AND NON-SMALL CELL (NSCLC)LUNG CARCINOMAS;772
7.3.5.34.1;ABSTRACT;772
7.3.5.34.2;KEYWORDS;772
7.3.5.34.3;INTRODUCTION;772
7.3.5.34.4;RESULTS;772
7.3.5.34.5;DISCUSSION;774
7.3.5.34.6;ACKNOWLEDGMENT;774
7.3.5.34.7;REFERENCES;774
7.3.5.35;CHAPTER 183. TPA, CEA AND CA-19-9 TESTS INS UR VEIL LING PATIENTS WITH BREASTAND GASTROINTESTINAL CANCER;776
7.3.5.35.1;ABSTRACT;776
7.3.5.35.2;KEYWORDS;776
7.3.5.35.3;INTRODUCTION;776
7.3.5.35.4;MATERIALS AND METHODS;777
7.3.5.35.5;RESULTS;777
7.3.5.35.6;DISCUSSION;779
7.3.5.35.7;REFERENCES;779
7.3.5.36;CHAPTER 184. CARCINOEMBRYONIC ANTIGEN (CEA)AND TISSUE POLYPEPTIDE ANTIGEN(TPA) IN NORMAL AND NEOPLASTICHUMAN TISSUES;780
7.3.5.36.1;ABSTRACT;780
7.3.5.36.2;KEY WORDS;780
7.3.5.36.3;INTRODUCTION;780
7.3.5.36.4;MATERIAL AND METHODS;780
7.3.5.36.5;RESULTS AND DISCUSSION;781
7.3.5.36.6;ACKNOWLEDGEMENT;783
7.3.5.36.7;REFERENCES;783
7.3.5.37;CHAPTER 185. PRELIMINARY STUDIES TO COMPARESENSITIVITY OF TISSUE POLYPEPTIDEANTIGEN (TPA) WITHCA R CINOEMBR YONIC ANTIGEN (CEA) ASUNIVERSAL TUMOR MARKERS;784
7.3.5.37.1;MATERIALS AND METHODS;784
7.3.5.37.2;RESULTS;784
7.3.5.37.3;DISCUSSION;786
7.3.5.37.4;REFERENCES;786
7.3.5.38;CHAPTER 186. SERUM LEVELS OF TPA AND CA 12-5 INPATIENTS WITH OVARIAN CARCINOMA;788
7.3.5.38.1;ABSTRACT;788
7.3.5.38.2;KEYWORDS;788
7.3.5.38.3;INTRODUCTION;788
7.3.5.38.4;MATERIAL AND METHODS;788
7.3.5.38.5;RESULTS;789
7.3.5.38.6;DISCUSSION;789
7.3.5.38.7;ACKNOWLEDGEMENT;791
7.3.5.38.8;REFERENCES;791
7.3.5.39;CHAPTER 187. PROGNOSTIC VALUES OF TPA, CEA ANDTHEIR COMBINATION BY PRODUCTFORMATION IN DIFFERENT CANCERLOCATIONS;792
7.3.5.39.1;ABSTRACT;792
7.3.5.39.2;KEY WORDS;792
7.3.5.39.3;INTRODUCTION;792
7.3.5.39.4;MATERIAL AND METHODS;792
7.3.5.39.5;RESULTS;793
7.3.5.39.6;DISCUSSION;795
7.3.5.39.7;REFERENCES;795
7.3.5.40;CHAPTER 188. TN, A GENERAL CARCINOMAASSOCIATEDANTIGEN;796
7.3.5.40.1;ABSTRACT;796
7.3.5.40.2;KEYWORDS;796
7.3.5.40.3;INTRODUCTION;796
7.3.5.40.4;MATERIALS AND METHODS;796
7.3.5.40.5;RESULTS AND DISCUSSION;798
7.3.5.40.6;REFERENCES;799
7.3.5.41;CHAPTER 189. MONOCLONAL ANTIBODIES SPECIFICFOR HUMAN THOMSEN-FRIEDENREICH(T) AND Tn BLOOD GROUP PRECURSORANTIGENS;802
7.3.5.41.1;ABSTRACT;802
7.3.5.41.2;KEYWORDS;802
7.3.5.41.3;INTRODUCTION;802
7.3.5.41.4;MATERIALS AND METHODS;802
7.3.5.41.5;RESULTS AND DISCUSSION;803
7.3.5.41.6;ACKNOWLEDGEMENT;803
7.3.5.41.7;REFERENCES;804
7.3.5.42;CHAPTER 190. T-ANTIGENS: MARKERS OF MALIGNANTTRANSFORMATION OF THE COLON;806
7.3.5.42.1;ABSTRACT;806
7.3.5.42.2;INTRODUCTION;806
7.3.5.42.3;MATERIALS AND METHODS;806
7.3.5.42.4;RESULTS;807
7.3.5.42.5;DISCUSSION;809
7.3.5.42.6;REFERENCES;809
7.3.5.43;CHAPTER 191. PRECLINICAL AND CLINICALEVALUATION OF A MONOCLONALANTIBODY TO A HUMAN MELANOMAASSOCIATEDANTIGEN;810
7.3.5.43.1;ABSTRACT;810
7.3.5.43.2;KEYWORDS;810
7.3.5.43.3;INTRODUCTION;810
7.3.5.43.4;MATERIALS AND METHODS;810
7.3.5.43.5;RESULTS;811
7.3.5.43.6;DISCUSSION;813
7.3.5.43.7;REFERENCES;814
7.3.5.44;CHAPTER 192. CLINICAL RELEVANCE OF HUMANONCOFETAL ANTIGEN (HÖFA) AS AMARKER OF TUMOR BURDEN;816
7.3.5.44.1;ABSTRACT;816
7.3.5.44.2;KEY WORDS;816
7.3.5.44.3;INTRODUCTION;816
7.3.5.44.4;METHODS AND RESULTS;817
7.3.5.44.5;DISCUSSION AND CONCLUDING REMARKS;818
7.3.5.44.6;ACKNOWLEDGEMENT;819
7.3.5.44.7;REFERENCES;819
7.3.5.45;CHAPTER 193. THE PRACTICAL USEFULNESS OF TUMORMARKERS IN ONCOLOGY;820
7.3.5.45.1;ABSTRACT;820
7.3.5.45.2;KEYWORDS;820
7.3.5.45.3;INTRODUCTION;820
7.3.5.45.4;METHODS;820
7.3.5.45.5;RESULTS;821
7.3.5.45.6;DISCUSSION;822
7.3.5.45.7;ACKNOWLEDGEMENTS;822
7.3.5.45.8;REFERENCES;822
7.3.5.46;CHAPTER 194. FIBRONECTIN IN MALIGNANCIES;824
7.3.5.46.1;ABSTRACT;824
7.3.5.46.2;KEYWORDS;824
7.3.5.46.3;INTRODUCTION;824
7.3.5.46.4;MATERIALS and METHODS PATIENTS;824
7.3.5.46.5;RESULTS;826
7.3.5.46.6;DISCUSSION;826
7.3.5.46.7;ACKNOWLEDGEMENT;827
7.3.5.46.8;REFERENCES;827
7.3.5.47;CHAPTER 195. TUMOR SPECIFIC CHARACTERISTICS OFA PTERIDINE „ BINDING ALPHArACIDGLYCOPROTEIN (AGPM) AND ITSMITOGENIC ACTIVITY;828
7.3.5.47.1;ABSTRACT;828
7.3.5.47.2;KEYWORDS;828
7.3.5.47.3;INTRODUCTION;828
7.3.5.47.4;RESULTS;828
7.3.5.47.5;DISCUSSION;830
7.3.5.47.6;REFERENCES;831
7.3.5.48;CHAPTER 196. A FRESH LOOK AT C REACTIVEPROTEIN MEASUREMENTS;832
7.3.5.48.1;ABSTRACT;832
7.3.5.48.2;KEYWORDS;832
7.3.5.48.3;INTRODUCTION;832
7.3.5.48.4;MATERIALS AND METHODS;832
7.3.5.48.5;RESULTS;834
7.3.5.48.6;CONCLUSION;834
7.3.5.48.7;REFERENCES;835
7.3.5.49;CHAPTER 197. DEMONSTRATION OF IMMUNECOMPLEXES AND THEIR POSSIBLE ROLEIN CANCER;836
7.3.5.49.1;MATERIAL AND METHODS;836
7.3.5.49.2;RESULTS;836
7.3.5.49.3;DISCUSSION;837
7.3.5.49.4;REFERENCES;838
7.3.5.50;CHAPTER 198. ROLE OF IMMUNE COMPLEXES INTUMOR ASSOCIATED IMMUNITY OFPATIENTS WITH PROSTATIC CANCER;840
7.3.5.50.1;ABSTRACT;840
7.3.5.50.2;KEYWORDS;840
7.3.5.50.3;INTRODUCTION;840
7.3.5.50.4;MATERIALS AND METHODS;840
7.3.5.50.5;RESULTS AND DISCUSSION;841
7.3.5.50.6;REFERENCES;843
7.3.5.51;CHAPTER 199. FURTHER STUDY ON THE S-100 ANTIGENIN NEOPLASTIC TISSUES;844
7.3.5.51.1;ABSTRACT;844
7.3.5.51.2;KEYWORDS;844
7.3.5.51.3;INTRODUCTION;844
7.3.5.51.4;EXPERIMENTAL PROCEDURES;844
7.3.5.51.5;RESULTS AND DISCUSSION;845
7.3.5.51.6;ACKNOWLEDGEMENTS;846
7.3.5.51.7;REFERENCES;846
7.3.5.52;CHAPTER 200. DETECTION OF THE DETERMINANTS ONBLOOD GROUP Ç ANTIGEN IN SERA OFCANCER PATIENTS WITH MONOCLONALANTIBODIES;848
7.3.5.52.1;ABSTRACT;848
7.3.5.52.2;KEYWORDS;848
7.3.5.52.3;INTRODUCTION;848
7.3.5.52.4;MATERIALS AND METHODS;848
7.3.5.52.5;RESULTS AND DISCUSSIONS;849
7.3.5.52.6;ACKNOWLEDGEMENTS;851
7.3.5.52.7;REFERENCES;851
7.3.5.53;CHAPTER 201. CHARACTERIZATION OF MONOCLONALANTIBODIES SPECIFIC FOR A HIGHMOLECULAR WEIGHT GLYCOPROTEINSECRETED FROM ACTIVATED HUMANBLOOD PLATELETS;852
7.3.5.53.1;ABSTRACT;852
7.3.5.53.2;KEYWORDS;852
7.3.5.53.3;INTRODUCTION;852
7.3.5.53.4;MATERIALS AND METHODS;852
7.3.5.53.5;RESULTS AND DISCUSSION;853
7.3.5.53.6;ACKNOWLEDGEMENTS;857
7.3.5.53.7;REFERENCES;857
7.3.5.54;CHAPTER 202. CHARACTERIZATION OF AMONOCLONAL ANTIBODY DIRECTEDAGAINST A PLATELET ALPHA-GRANULEGLYCOPROTEIN;858
7.3.5.54.1;ABSTRACT;858
7.3.5.54.2;KEYWORDS;858
7.3.5.54.3;INTRODUCTION;858
7.3.5.54.4;MATERIALS AND METHODS;858
7.3.5.54.5;RESULTS AND DISCUSSION;859
7.3.5.54.6;ACKNOWLEDGMENT;861
7.3.5.54.7;REFERENCES;861
7.3.6;B.6. Tumors;862
7.3.6.1;CHAPTER 203. ENHANCED EXPRESSION OF SURFACETUMOR ASSOCIATED ANTIGENS ONHUMAN BREAST AND COLON TUMORCELLS BY RECOMBINANT HUMANINTERFERON;862
7.3.6.1.1;ABSTRACT;862
7.3.6.1.2;KEYWORDS;862
7.3.6.1.3;INTRODUCTION;862
7.3.6.1.4;MATERIALS AND METHODS;862
7.3.6.1.5;RESULTS;863
7.3.6.1.6;DISCUSSION;866
7.3.6.1.7;ACKNOWLEDGEMENTS;867
7.3.6.1.8;REFERENCES;867
7.3.6.2;CHAPTER 204. HUMAN AND MURINE MONOCLONALANTIBODIES AGAINST HUMANMAMMARY CARCINOMA CELLS;868
7.3.6.2.1;ABSTRACT;868
7.3.6.2.2;KEYWORDS;868
7.3.6.2.3;INTRODUCTION;868
7.3.6.2.4;MATERIAL AND METHODS;869
7.3.6.2.5;RESULTS AND DISCUSSION;869
7.3.6.2.6;REFERENCES;871
7.3.6.3;CHAPTER 205. MODIFICATION OF THE REGULATION OFINTERLEUKIN 2 (IL2) IN HUMAN BREASTCANCER;872
7.3.6.3.1;ABSTRACT;872
7.3.6.3.2;KEYWORDS;872
7.3.6.3.3;INTRODUCTION;872
7.3.6.3.4;MATERIALS AND METHODS;872
7.3.6.3.5;RESULTS;873
7.3.6.3.6;CONCLUSION;875
7.3.6.3.7;DISCUSSION;875
7.3.6.3.8;ACKNOWLEDGEMENT;875
7.3.6.3.9;REFERENCES;875
7.3.6.4;CHAPTER 206. COMPARISON BETWEEN GLYCOLYTICENZYME ACTIVITIES IN BENIGN ANDMALIGNANT BREAST TUMORS;876
7.3.6.4.1;ABSTRACT;876
7.3.6.4.2;KEY WORDS;876
7.3.6.4.3;INTRODUCTION;876
7.3.6.4.4;MATERIALS AND METHODS;876
7.3.6.4.5;RESULTS;877
7.3.6.4.6;DISCUSSION;878
7.3.6.4.7;REFERENCES;879
7.3.6.5;CHAPTER 207. VALUE OF DETERMINATION OF CEAAND PHI LEVELS IN BREAST TISSUE:CORRELATION WITH STEROIDRECEPTORS;880
7.3.6.5.1;MATERIAL AND METHODS;880
7.3.6.5.2;DISCUSSION;882
7.3.6.5.3;ACKNOWLEDGEMENTS;882
7.3.6.5.4;REFERENCES;883
7.3.6.6;CHAPTER 208. CLINICAL USEFULNESS OF THESIMULTANEOUS DETERMINATION OFTUMOR MARKERS AND STEROIDRECEPTORS IN BREAST CANCER;884
7.3.6.6.1;INTRODUCTION;884
7.3.6.6.2;MATERIAL AND METHODS;884
7.3.6.6.3;RESULTS;884
7.3.6.6.4;DISCUSSION;885
7.3.6.6.5;ACKNOWLEDGEMENTS;887
7.3.6.6.6;REFERENCES;887
7.3.6.7;CHAPTER 209. VALUE OF BIOCHEMICAL EXAMINATIONOF CYST FLUID IN THE CLASSIFICATIONOF MAMMARY FIBROCYSTIC DISEASE;888
7.3.6.7.1;MATERIAL AND METHODS;888
7.3.6.7.2;RESULTS:;888
7.3.6.7.3;DISCUSSION:;889
7.3.6.7.4;ACKNOWLEDGMENTS;890
7.3.6.7.5;REFERENCES;890
7.3.6.8;CHAPTER 210. REGULATION OF CORTISOLMETABOLISM BY LYMPHOCYTES;892
7.3.6.8.1;ABSTRACT;892
7.3.6.8.2;KEY WORDS;892
7.3.6.8.3;INTRODUCTION;892
7.3.6.8.4;METHODS AND RESULTS;893
7.3.6.8.5;DISCUSSION;895
7.3.6.8.6;ACKNOWLEDGEMENT;895
7.3.6.8.7;REFERENCES;895
7.3.6.9;CHAPTER 211. GALACTOSYLTRANSFERASE ACTIVITY/SIALYLTRANSFERASE ACTIVITY AS ANINDEX OF MEMBRANE GLYCOSYLATIONOF LYMPHOCYTE SUBPOPULATIONS;896
7.3.6.9.1;ABSTRACT;896
7.3.6.9.2;KEYWORDS;896
7.3.6.9.3;INTRODUCTION;896
7.3.6.9.4;MATERIALS AND METHODS;896
7.3.6.9.5;RESULTS;897
7.3.6.9.6;DISCUSSION;898
7.3.6.9.7;ACKNOWLEDGEMENT;899
7.3.6.9.8;REFERENCES;899
7.3.6.10;CHAPTER 212. MONITORING OF A HUMAN Â CELLLYMPHOMA WITH MONOCLONAL ANTIIDIOTYPEANTIBODIES;900
7.3.6.10.1;ABSTRACT;900
7.3.6.10.2;KEYWORDS;900
7.3.6.10.3;INTRODUCTION;900
7.3.6.10.4;MATERIAL AND METHODS;900
7.3.6.10.5;RESULTS AND DISCUSSION;901
7.3.6.10.6;REFERENCES;903
7.3.6.11;CHAPTER 213. MONOCLONAL ANTIBODY (HD 39)REACTIVE WITH A HUMAN ÂLYMPHOCYTE SPECIFIC ANTIGENEXPRESSED ON LATE STAGES OF ÂCELL MATURATION;904
7.3.6.11.1;ABSTRACT;904
7.3.6.11.2;KEYWORDS;904
7.3.6.11.3;INTRODUCTION;904
7.3.6.11.4;MATERIALS AND METHODS;904
7.3.6.11.5;RESULTS AND DISCUSSION;905
7.3.6.11.6;REFERENCES;907
7.3.6.12;CHAPTER 214. INTERRELATIONSHIP OF HAIRY CELLLEUKEMIA AND PHORBOL ESTERINDUCED B-CELL "LYMPHOCYTES" ASDEMONSTRATED BY MONOCLONALANTIBODIES;908
7.3.6.12.1;ABSTRACT;908
7.3.6.12.2;KEYWORDS;908
7.3.6.12.3;INTRODUCTION;908
7.3.6.12.4;MATERIAL AND METHODS;908
7.3.6.12.5;RESULTS;909
7.3.6.12.6;DISCUSSION;910
7.3.6.12.7;ACKNOWLEDGMENTS;911
7.3.6.12.8;REFERENCES;911
7.3.6.13;CHAPTER 215. IDENTIFICATION AND MONITORING OFTERMINAL DEOXYNUCLEOTIDYLTRANSFERASE POSITIVE CELLS IN THECEREBROSPINAL FLUID OF CHILDRENWITH LYMPHOID MALIGNANCIES;912
7.3.6.13.1;ABSTRACT;912
7.3.6.13.2;KEY WORDS;912
7.3.6.13.3;INTRODUCTION;912
7.3.6.13.4;MATERIALS AND METHODS;913
7.3.6.13.5;RESULTS;913
7.3.6.13.6;DISCUSSION;914
7.3.6.13.7;ACKNOWLEDGMENT;915
7.3.6.13.8;REFERENCES;915
7.3.6.14;CHAPTER 216. BLA: A GLYCOLIPID ANTIGENASSOCIATED WITH BURKITTSLYMPHOMA CELLS;916
7.3.6.14.1;MATERIAL and METHODS;916
7.3.6.14.2;RESULTS AND DISCUSSION;917
7.3.6.14.3;ACKNOWLEDGEMENT;918
7.3.6.14.4;REFERENCES;918
7.3.6.15;CHAPTER 217. EXPRESSION OF Â CELL MARKERS INCENTROBLASTICICENTROCYTIC NONHODGKINSLYMPHOMAS;920
7.3.6.15.1;ABSTRACT;920
7.3.6.15.2;KEYWORDS;920
7.3.6.15.3;INTRODUCTION;920
7.3.6.15.4;MATERIALS AND METHODS;920
7.3.6.15.5;RESULTS;921
7.3.6.15.6;DISCUSSION;922
7.3.6.15.7;ACKNOWLEDGMENT;922
7.3.6.15.8;REFERENCES;922
7.3.6.16;CHAPTER 218. BINDING AND ENDOCYTOSIS OF RATMONOCLONAL ANTIIMMUNOGLOBULINANTIBODIES BY HUMAN LYMPHOMACELLS;924
7.3.6.16.1;ABSTRACT;924
7.3.6.16.2;KEYWORDS;924
7.3.6.16.3;INTRODUCTION;924
7.3.6.16.4;MATERIAL AND METHODS;924
7.3.6.16.5;RESULTS;925
7.3.6.16.6;DISCUSSION;927
7.3.6.16.7;ACKNOWLEDGEMENTS;927
7.3.6.16.8;REFERENCES;927
7.3.6.17;CHAPTER 219. A MONOCLONAL ANTIBODY (HAN-PC1),REACTING WITH A MATURATIONANTIGEN ON PLASMA CELLS;928
7.3.6.17.1;ABSTRACT;928
7.3.6.17.2;KEYWORDS;928
7.3.6.17.3;INTRODUCTION;928
7.3.6.17.4;MATERIALS AND METHODS;928
7.3.6.17.5;RESULTS AND DISCUSSION;929
7.3.6.17.6;ACKNOWLEDGEMENTS;931
7.3.6.17.7;REFERENCES;931
7.3.6.18;CHAPTER 220. MONOCLONAL ANTIBODY BI-3C5 REACTSSPECIFICALLY WITH M1/M2-ACUTEMYELOID LEUKAEMIAS AND MOSTNON-B NON-T ACUTE LYMPHOCYTICLEUKAEMIAS, AND RECOGNISES ASMALL POPULATION OF IMMATURECELLS IN NORMAL BONE MARROW;934
7.3.6.18.1;ABSTRACT;934
7.3.6.18.2;KEYWORDS;934
7.3.6.18.3;INTRODUCTION;934
7.3.6.18.4;METHODS;934
7.3.6.18.5;RESULTS;935
7.3.6.18.6;DISCUSSION;936
7.3.6.18.7;ACKNOWLEDGEMENTS;937
7.3.6.18.8;REFERENCES;937
7.3.6.19;CHAPTER 221. ALTERED HELPER-T, SUPPRESSOR-TCELL REPRESENTATION IN THOSE WITHADVANCED STAGE PROSTATIC CANCER;938
7.3.6.19.1;ABSTRACT;938
7.3.6.19.2;KEY WORDS;938
7.3.6.19.3;INTRODUCTION;938
7.3.6.19.4;MATERIALS AND METHODS;939
7.3.6.19.5;RESULTS;939
7.3.6.19.6;DISCUSSION;942
7.3.6.19.7;ACKNOWLEDGEMENT;943
7.3.6.19.8;REFERENCES;943
7.3.6.20;CHAPTER 222. ORAL ADJUVANTS WHICH ENHANCE ORREPLACE Ô CELLS FOR IgA RESPONSES;944
7.3.6.20.1;ABSTRACT;944
7.3.6.20.2;KEYWORDS;944
7.3.6.20.3;INTRODUCTION;944
7.3.6.20.4;INDUCTION OF IgA IMMUNE RESPONSES;945
7.3.6.20.5;ORAL ADJUVANTS ENHANCE IgA IMMUNE RESPONSES;945
7.3.6.20.6;ORAL ADJUVANTS REPLACE Ô CELL FUNCTION FOR IgA RESPONSES;946
7.3.6.20.7;SUMMARY;948
7.3.6.20.8;ACKNOWLEDGEMENTS;949
7.3.6.20.9;REFERENCES;949
7.3.6.21;CHAPTER 223. DETECTION OF ANTIBODIES AGAINSTHERPES SIMPLEX VIRUSES IN SERA OFPATIENTS WITH CERVICAL CANCER BYUSING THE WESTERN BLOTTINGTECHNIQUE;950
7.3.6.21.1;ABSTRACT;950
7.3.6.21.2;KEYWORDS;950
7.3.6.21.3;INTRODUCTION;950
7.3.6.21.4;MATERIALS AND METHODS;950
7.3.6.21.5;RESULTS;951
7.3.6.21.6;DISCUSSION;952
7.3.6.21.7;ACKNOWLEDGEMENTS;953
7.3.6.21.8;REFERENCES;953
7.3.6.22;CHAPTER 224. DEFINITION BY MURINE MONOCLONALANTIBODIES OF CELL SURFACESTRUCTURES EXERTING Fe- ANDC3bi-RECEPTOR ACTIVITY IN VIVO;954
7.3.6.22.1;ABSTRACT;954
7.3.6.22.2;KLYWUKUb;954
7.3.6.22.3;INTRODUCTION;954
7.3.6.22.4;MATERIALS and METHODS;954
7.3.6.22.5;RESULTS;955
7.3.6.22.6;DISCUSSION;956
7.3.6.22.7;REFERENCES;956
7.3.6.22.8;ACKNOWLEDGMENTS;956
7.3.6.23;CHAPTER 225. INCREASED UROKINASE-ÔÕÑÅPLASMINOGEN ACTIVATOR IN TUMORSOF THE UROGENITAL TRACT;958
7.3.6.23.1;ABSTRACT;958
7.3.6.23.2;KEY WORDS;958
7.3.6.23.3;INTRODUCTION;958
7.3.6.23.4;MATERIALS AND METHODS;959
7.3.6.23.5;RESULTS;959
7.3.6.23.6;DISCUSSION;960
7.3.6.23.7;REFERENCES;961
7.3.6.24;CHAPTER 226. RADIOIMMUNOASSAY AND BINDINGCAPACITY OF SEX HORMONE BINDINGGLOBULIN (SHBG) IN PATIENTS WITHGYNAECOLOGICAL CANCER;962
7.3.6.24.1;ABSTRACT;962
7.3.6.24.2;KEYWORDS;962
7.3.6.24.3;INTRODUCTION;962
7.3.6.24.4;METHODS;962
7.3.6.24.5;RESULTS AND DISCUSSION;963
7.3.6.24.6;ACKNOWLEDGEMENT;965
7.3.6.24.7;REFERENCES;965
7.3.6.25;CHAPTER 227. SOLATION OF HEPATITIS Â SURFACEANTIGEN FROM HUMAN PLASMA BYAFFINITY CHROMATOGRAPHY USINGMONOCLONAL ANTIBODY;966
7.3.6.25.1;ABSTRACT;966
7.3.6.25.2;KEYWORDS;966
7.3.6.25.3;INTRODUCTION;966
7.3.6.25.4;HYBRIDOMA PRODUCTION;966
7.3.6.25.5;ASCITES PRODUCTION;966
7.3.6.25.6;PURIFICATION OF MONOCLONAL anti-HBs;966
7.3.6.25.7;PREPARATION OF ANTI-HBs AFFINITY MEDIUM;967
7.3.6.25.8;RECOVERY OF HBsAg FROM HUMAN PLASMA BY ANTI-HBs AFFINITY CHROMATOGRAPHY;967
7.3.6.25.9;ISOPYCNIC CENTRIFUGATION OF HBsAg RECOVERED BY AFFINITY CHROMATOGRAPHY;968
7.3.6.25.10;SUMMARY;968
7.3.6.25.11;ACKNOWLEDGEMENT;968
7.3.6.25.12;REFERENCES;968
7.3.6.26;CHAPTER 228. COMPETITIVE SCREENING ANDDETERMINATION OF THE AFFINITYCONSTANTS FOR THECHARACTERIZATION OF MONOCLONALANTIBODIES AGAINST HUMANCHORIONIC SOMATOMAMMOTROPIN;970
7.3.6.26.1;ABSTRACT;970
7.3.6.26.2;KEY WORDS;970
7.3.6.26.3;iNTRODUCTION;970
7.3.6.26.4;MATERIALS AND METHODS;970
7.3.6.26.5;RESULTS AND DISCUSSION;972
7.3.6.26.6;REFERENCES;973
7.3.6.27;CHAPTER 229. FLOW CYTOMETRIC ANALYSIS OF MIXEDCELL POPULATIONS USING ANTIBODIESTO CYTOKERATIN;974
7.3.6.27.1;ABSTRACT;974
7.3.6.27.2;INTRODUCTION;974
7.3.6.27.3;MATERIALS AND METHODS;974
7.3.6.27.4;RESULTS;975
7.3.6.27.5;DISCUSSION;977
7.3.6.27.6;REFERENCES;977
7.3.6.28;CHAPTER 230. ISOLATION AND CHARACTERIZATION OFPROSTATIC TUMOR EFFUSIONS;978
7.3.6.28.1;ABSTRACT;978
7.3.6.28.2;KEYWORDS;978
7.3.6.28.3;INTRODUCTION;978
7.3.6.28.4;MATERIALS AND METHODS;978
7.3.6.28.5;RESULTS;979
7.3.6.28.6;DISCUSSION;981
7.3.6.28.7;ACKNOWLEDGEMENT;981
7.3.6.28.8;REFERENCES;981
7.3.6.29;CHAPTER 231. MONOCLONAL ANTIBODIES FORPURIFICATION AND RIA OF NATURALAND RECOMBINANT HUMANINTERFERON-*, -$AND-y;982
7.3.6.29.1;ABSTRACT;982
7.3.6.29.2;KEYWORDS;982
7.3.6.29.3;INTRODUCTION;982
7.3.6.29.4;MATERIALS AND METHODS;982
7.3.6.29.5;RESULTS AND DISCUSSION;982
7.3.6.29.6;ACKNOWLEDGEMENT;985
7.3.6.29.7;REFERENCES;985
7.3.6.30;CHAPTER 232. ISOLATION AND CHARACTERIZATION OFANTI-Z-DNA ANTIBODIES IN SERA OFPATIENTS WITH S LE;986
7.3.6.30.1;KEYWORDS;986
7.3.6.30.2;ABSTRACT;986
7.3.6.30.3;INTRODUCTION;986
7.3.6.30.4;MATERIALS & METHODS;986
7.3.6.30.5;RESULTS & DISCUSSION;988
7.3.6.30.6;Acknowledgement;989
7.3.6.30.7;References;989
7.4;SECTION C: Advances in Separation of Protides;990
7.4.1;C.1. Color labelling;992
7.4.1.1;CHAPTER 233. HIGH SENSITIVITY ANALYSIS OF AMINOACIDS, PEPTIDES AND PROTEINS BYCOLOR LABELLING TECHNIQUES;992
7.4.1.1.1;SUMMARY;992
7.4.1.1.2;INTRODUCTION;992
7.4.1.1.3;RFFERENCES;997
7.4.2;C.2. 2-D E. P.;998
7.4.2.1;CHAPTER 234. NEW PROTEINS UNIQUE TOCEREBROSPINAL FLUID (CSF)IDENTIFIED BY TWO-DIMENSIONALELECTROPHORESIS (2DE);998
7.4.2.1.1;ABSTRACT;998
7.4.2.1.2;KEYWORDS;998
7.4.2.1.3;INTRODUCTION;998
7.4.2.1.4;METHODS;999
7.4.2.1.5;RESULTS AND DISCUSSION;999
7.4.2.1.6;REFERENCES;999
7.4.2.2;CHAPTER 235. A SIMPLE METHOD FOR QUANTITATIVEANALYSIS OF PROTEIN IN SPOTSSEPARATED BY TWO-DIMENSIONALPOLYACRYLAMIDE GELELECTROPHORESIS AND ITSAPPLICATIONS;1002
7.4.2.2.1;ABSTRACT;1002
7.4.2.2.2;KEYWARDS;1002
7.4.2.2.3;INTRODUCTION;1002
7.4.2.2.4;EXPERIMENTAL;1002
7.4.2.2.5;RESULTS AND DISCUSSION;1003
7.4.2.2.6;ACKNOWLEDGEMENT;1005
7.4.2.2.7;REFERENCES;1005
7.4.2.3;CHAPTER 236. TWO-DIMENSIONAL AFFINITYELECTROPHORESIS: ITS APPLICATIONTO SEPARATION OF INDIVIDUALIMMUNOGLOBULINS FROMHETEROGENEOUS ANTIBODIES;1006
7.4.2.3.1;ABSTRACT;1006
7.4.2.3.2;KEYWORDS;1006
7.4.2.3.3;INTRODUCTION;1006
7.4.2.3.4;MATERIALS AND METHODS;1006
7.4.2.3.5;RESULTS;1007
7.4.2.3.6;REFERENCES;1009
7.4.2.4;CHAPTER 237. ANALYSIS OF GENETIC MUSCLEDISORDERS BY TWO-DIMENSIONALELECTROPHORESIS;1010
7.4.2.4.1;ABSTRACT;1010
7.4.2.4.2;KEYWORDS;1010
7.4.2.4.3;INTRODUCTION;1010
7.4.2.4.4;ONE-DIMENSIONAL ELECTROPHORESIS;1010
7.4.2.4.5;OPTIMIZATION OF 2D-PAGE PROCEDURE;1010
7.4.2.4.6;RESULTS OF 2D-PAGE ANALYSIS OF DMD;1011
7.4.2.4.7;PROBLEMS OF METHODOLOGY;1012
7.4.2.4.8;PROBLEMS OF SAMPLE COMPARISONS;1012
7.4.2.4.9;DIFFICULTIES IN THE ANALYSIS OF GENETIC DISEASES;1012
7.4.2.4.10;FUTURE STRATEGIES;1013
7.4.2.4.11;ACKNOWLEDGEMENTS;1013
7.4.2.4.12;REFERENCES;1013
7.4.2.5;CHAPTER 238. MULTIDIMENSIONAL ELECTROPHORESISOF PROTEINS;1014
7.4.2.5.1;ABSTRACT;1014
7.4.2.5.2;KEYWORDS;1014
7.4.2.5.3;INTRODUCTION;1014
7.4.2.5.4;METHODS, RESULTS AND DISCUSSION;1015
7.4.2.5.5;ACKNOWLEDGEMENT;1019
7.4.2.5.6;REFERENCES;1019
7.4.3;C.3. E. P.;1020
7.4.3.1;CHAPTER 239. A CONTINUOUS ELUTION PROCEDUREFOR AGAROSE SUSPENSIONELECTROPHORESIS OF NEUROPEPTIDES;1020
7.4.3.1.1;KEYWORDS;1020
7.4.3.1.2;INTRODUCTION;1020
7.4.3.1.3;MATERIALS AND METHODS;1020
7.4.3.1.4;RESULTS;1022
7.4.3.1.5;DISCUSSION;1022
7.4.3.1.6;ACKNOWLEDGEMENTS;1023
7.4.3.1.7;REFERENCES;1023
7.4.3.2;CHAPTER 240. ELECTROPHORETIC HETEROGENEITY OFHUMAN PROLACTIN IN PREGNANCYURINE;1024
7.4.3.2.1;ABSTRACT;1024
7.4.3.2.2;KEYWORDS;1024
7.4.3.2.3;INTRODUCTION;1024
7.4.3.2.4;MATERIALS AND METHODS;1024
7.4.3.2.5;RESULT;1025
7.4.3.2.6;DISCUSSION;1026
7.4.3.2.7;ACKNOWLEDGEMENT;1027
7.4.3.2.8;REFERENCES;1027
7.4.3.3;CHAPTER 241. NITROCELLULOSE BLOTTING OF CSFAND URINE PROTIDES;1028
7.4.3.3.1;ABSTRACT;1028
7.4.3.3.2;KEYWORDS;1028
7.4.3.3.3;INTRODUCTION;1028
7.4.3.3.4;METHODS;1029
7.4.3.3.5;RESULTS/DISCUSSION;1029
7.4.3.3.6;REFERENCES;1029
7.4.3.4;CHAPTER 242. IMMUNOLOGICAL CHARACTERIZATIONOF CREATINE KINASE MM SUB-BANDSAFTER ISOELECTRIC FOCUSING ANDELECTROBLOTTING;1030
7.4.3.4.1;ABSTRACT;1030
7.4.3.4.2;KEYWORDS;1030
7.4.3.4.3;INTRODUCTION;1030
7.4.3.4.4;MATERIAL AND METHODS;1031
7.4.3.4.5;RESULTS AND DISCUSSION;1031
7.4.3.4.6;CONCLUSION;1032
7.4.3.4.7;ACKNOWLEDGEMENT;1032
7.4.3.4.8;REFERENCES;1032
7.4.3.5;CHAPTER 243. pH GRADIENT MANIPULATION INISOELECTRIC FOCUSING USINGZWITTERIONIC BUFFERS;1034
7.4.3.5.1;ABSTRACT;1034
7.4.3.5.2;KEYWORDS;1034
7.4.3.5.3;INTRODUCTION;1034
7.4.3.5.4;MATERIALS AND METHOD;1035
7.4.3.5.5;RESULTS AND DISCUSSION;1035
7.4.3.5.6;REFERENCES;1037
7.4.3.6;CHAPTER 244. PRESUMPTIVE IDENTIFICATION OFHUMAN HEMOGLOBIN VARIANTS BYCOMBINED ELECTROPHORESIS;1038
7.4.3.6.1;ABSTRACT;1038
7.4.3.6.2;KEYWORDS;1038
7.4.3.6.3;INTRODUCTION;1038
7.4.3.6.4;ACKNOWLEDGEMENTS;1040
7.4.3.6.5;REFERENCES;1040
7.4.3.7;CHAPTER 245. SPIROPLASMA CITRI MEMBRANEPROTEIN ANALYSIS BY SODIUMDEOXYCHOLATE-CROSSEDIMMUNOELECTROPHORESIS WITH ASIEVING FIRST DIRECTIONAL GEL;1042
7.4.3.7.1;ABSTRACT;1042
7.4.3.7.2;KEYWORDS;1042
7.4.3.7.3;INTRODUCTION;1042
7.4.3.7.4;EXPERIMENTAL;1042
7.4.3.7.5;RESULTS AND DISCUSSION;1043
7.4.3.7.6;ACKNOWLEDGEMENT;1045
7.4.3.7.7;REFERENCES;1045
7.4.3.8;CHAPTER 246. CONCENTRATION OF PROTEINS BYAPPLICATION OF THE KOHLRAUSCHREGULATION FUNCTION;1046
7.4.3.8.1;ABSTRACT;1046
7.4.3.8.2;KEYWORDS;1046
7.4.3.8.3;INTRODUCTION;1046
7.4.3.8.4;MATERIALS AND METHODS;1046
7.4.3.8.5;RESULTS;1048
7.4.3.8.6;DISCUSSION;1048
7.4.3.8.7;REFERENCES;1048
7.4.3.9;CHAPTER 247. AN ANALYSIS OF THEM ICR OHE TER Ï GENEITY OF PIGFUMARASE;1050
7.4.3.9.1;ABSTRACT;1050
7.4.3.9.2;INTRODUCTION;1050
7.4.3.9.3;MATERIALS AND METHODS;1050
7.4.3.9.4;RESULTS;1051
7.4.3.9.5;DISCUSSION;1053
7.4.3.9.6;ACKNOWLEDGEMENTS;1053
7.4.3.9.7;REFERENCES;1053
7.4.3.10;CHAPTER 248. TWO DIMENSIONAL ANIONIC-CATIONICDETERGENTS POLYACRYLAMIDE GELELECTROPHORESIS: A NEW STRATEGYIN THE SEPARATION OF MEMBRANEPROTEINS;1054
7.4.3.10.1;ABSTRACT;1054
7.4.3.10.2;KEYWORDS;1054
7.4.3.10.3;INTRODUCTION;1054
7.4.3.10.4;RESULTS AND DISCUSSION;1055
7.4.3.10.5;CONCLUSION;1055
7.4.3.10.6;REFERENCES;1057
7.4.3.11;CHAPTER 249. METHODS FOR IDENTIFICATION ANDQUANTIFICATION OF ALKALINEPHOSPHATASE ISOENZYMES IN HUMANSERUM;1058
7.4.3.11.1;INTRODUCTION;1058
7.4.3.11.2;MATERIALS AND METHODS;1058
7.4.3.11.3;RESULTS;1059
7.4.3.11.4;DISCUSSION;1061
7.4.3.11.5;REFERENCES;1061
7.4.3.12;CHAPTER 250. STUDIES ON LMG (LOW-MOBILITYGROUP),A CLASS OF CHROMOSOMALPROTEINS FROM CALF THYMUS;1062
7.4.3.12.1;ABSTRACT;1062
7.4.3.12.2;KEY WORDS;1062
7.4.3.12.3;INTRODUCTION;1062
7.4.3.12.4;METHODS AND RESULTS;1062
7.4.3.12.5;REFERENCES;1064
7.4.4;C.4. H.P.L.C.;1066
7.4.4.1;CHAPTER 251. THE USE OF HPLC PROCEDURES IN THESTUDY OF HUMAN HEMOGLOBINVARIANTS;1066
7.4.4.1.1;ABSTRACT;1066
7.4.4.1.2;KEY WORDS;1066
7.4.4.1.3;INTRODUCTION;1066
7.4.4.1.4;ACKNOWLEDGEMENTS;1072
7.4.4.1.5;REFERENCES;1072
7.4.4.2;CHAPTER 252. USE OF HPLC TECHNIQUES ANDMONOCLONAL ANTIBODIES IN THESTUDY OF LEMUR HEMOGLOBINS;1074
7.4.4.2.1;ABSTRACT;1074
7.4.4.2.2;KEY WORDS;1074
7.4.4.2.3;INTRODUCTION;1074
7.4.4.2.4;MATERIALS AND METHODS;1075
7.4.4.2.5;RESULTS AND DISCUSSION;1075
7.4.4.2.6;ACKNOWLEDGMENTS;1077
7.4.4.2.7;REFERENCES;1077
7.4.4.3;CHAPTER 253. USE OF MINI COLUMN IN RP-HPLC FORTHE COMPLETE PRIMARY STRUCTUREDETERMINATION OF PROTEINS;1078
7.4.4.3.1;ABSTRACT;1078
7.4.4.3.2;KEYWORDS;1078
7.4.4.3.3;INTRODUCTION;1078
7.4.4.3.4;MATERIALS AND METHODS;1079
7.4.4.3.5;RESULTS AND DISCUSSION;1080
7.4.4.3.6;ACKNOLWEDGEMENT;1085
7.4.4.3.7;REFERENCES;1085
7.4.4.4;CHAPTER 254. THE USE OF ION EXCHANGE ANDREVERSED-PHASE HPLC FOR THEISOLATION AND CHARACTERIZATION OFINTERFERON GAMMA;1086
7.4.4.4.1;INTRODUCTION;1086
7.4.4.4.2;MATERIALS AND METHODS;1086
7.4.4.4.3;RESULTS AND DISCUSSION;1086
7.4.4.4.4;ACKNOWLEDGEMENT;1089
7.4.4.4.5;REFERENCES;1089
7.4.4.5;CHAPTER 255. HIGH-PERFORMANCE LIQUIDCHROMATOGRAPHY OF DETERGENTEXTRACTED HERPES SIMPLEX TYPE 1VIRIONS;1090
7.4.4.5.1;ABSTRACT;1090
7.4.4.5.2;KEYWORDS;1090
7.4.4.5.3;INTRODUCTION;1090
7.4.4.5.4;MATERIALS AND METHODS;1091
7.4.4.5.5;RESULTS AND DISCUSSION;1091
7.4.4.5.6;ACKNOWLEDGEMENTS;1093
7.4.4.5.7;REFERENCES;1093
7.4.4.6;CHAPTER 256. PURIFICATION OF CHROMOSOMAL HMGPROTEINS BY HPLC CHARACTERIZATIONOF TWO NEW SPECIES: HMG Ï ANDHMG X;1094
7.4.4.6.1;ABSTRACT;1094
7.4.4.6.2;KEYWORDS;1094
7.4.4.6.3;INTRODUCTION;1094
7.4.4.6.4;RESULTS AND DISCUSSION;1094
7.4.4.6.5;ACKNOWLEDGMENT;1096
7.4.4.6.6;REFERENCES;1096
7.4.4.7;CHAPTER 257. HIGH-PERFORMANCE LIQUIDCHROMATOGRAPHY OF VIRAL PROTEINSAS A TOOL IN THE DESIGN OFSYNTHETIC VACCINES;1098
7.4.4.7.1;ABSTRACT;1098
7.4.4.7.2;KEYWORDS;1098
7.4.4.7.3;INTRODUCTION;1098
7.4.4.7.4;MATERIALS AND METHODS;1099
7.4.4.7.5;RESULTS AND DISCUSSION;1099
7.4.4.7.6;ACKNOWLEDGEMENT;1101
7.4.4.7.7;REFERENCES;1101
7.4.4.8;CHAPTER 258. ISOLATION OF AN IMMUNOREACTIVETHYMOSIN FRACTION BYCHROMATOFOCUSING AND HIGHPERFORMANCELIQUIDCHROMA TOGRAPHY;1102
7.4.4.8.1;ABSTRACT;1102
7.4.4.8.2;KEYWORDS;1102
7.4.4.8.3;INTRODUCTION;1102
7.4.4.8.4;METHODS AND RESULTS;1102
7.4.4.8.5;DISCUSSION;1104
7.4.4.8.6;ACKNOWLEDGMENTS:;1105
7.4.4.8.7;REFERENCES;1105
7.4.4.9;CHAPTER 259. PEPTIDE SEPARATION USINGGUANIDINE-HCL DURING REVERSEPHASEHIGH PERFORMANCE LIQUIDCHROMA TOGRAPHY;1106
7.4.4.9.1;ABSTRACT;1106
7.4.4.9.2;INTRODUCTION;1106
7.4.4.9.3;MATERIALS AND METHODS;1106
7.4.4.9.4;RESULTS;1107
7.4.4.9.5;CONCLUSIONS;1109
7.4.4.9.6;ACKNOWLEDGMENTS;1109
7.4.4.9.7;REFERENCES;1109
7.4.4.10;CHAPTER 260. ISOLATION OF PEPTIDE FRAGMENTS OFTHE PYRIMIDINE BIOSYNTHETICCOMPLEX BY HPLC;1110
7.4.4.10.1;ABSTRACT;1110
7.4.4.10.2;KEYWORDS;1110
7.4.4.10.3;INTRODUCTION;1110
7.4.4.10.4;RESULTS;1110
7.4.4.10.5;ACKNOWLEDGEMENT;1113
7.4.4.10.6;REFERENCES;1113
7.4.4.11;CHAPTER 261. HIGH PERFORMANCE HYDROPHOBICINTERACTION CHROMATOGRAPHY OFPROTEINS: APPLICATION TO THEPURIFICATION OF BLACK MAMBAVENON;1114
7.4.4.11.1;ABSTRACT;1114
7.4.4.11.2;KEY WORDS;1114
7.4.4.11.3;INTRODUCTION;1114
7.4.4.11.4;MATERIALS AND METHODS;1117
7.4.4.11.5;RESULTS AND DISCUSSION;1117
7.4.4.12;CHAPTER 262. APPLICATION OF HPLC TO THESEPARATION OF GLYCOPROTEINS FROMENDOTHELIAL CELL CULTURE MEDIUM;1118
7.4.4.12.1;ABSTRACT;1118
7.4.4.12.2;KEYWORDS;1118
7.4.4.12.3;INTRODUCTION;1118
7.4.4.12.4;EXPERIMENTAL AND DISCUSSION;1118
7.4.4.12.5;REFERENCES;1121
7.4.4.13;CHAPTER 263. REVERSE-PHASE HIGH-PERFORMANCELIQUID CHROMATOGRAPHY OF VIRUSPROTEINS AND OTHER HYDROPHOBICPROTEINS;1122
7.4.4.13.1;ABSTRACT;1122
7.4.4.13.2;KEYWORDS;1122
7.4.4.13.3;INTRODUCTION;1122
7.4.4.13.4;ACKNOWLEDGEMENT;1125
7.4.4.13.5;REFERENCES;1125
7.4.4.14;CHAPTER 264. FAST PROTEIN LIQUIDCHROMATOGRAPHY OF IgA FRAGMENTS;1126
7.4.4.14.1;ABSTRACT;1126
7.4.4.14.2;KEYWORDS;1126
7.4.4.14.3;INTRODUCTION;1126
7.4.4.14.4;MATERIALS AND METHODS;1126
7.4.4.14.5;RESULTS AND DISCUSSION;1127
7.4.4.14.6;REFERENCES;1129
7.4.4.14.7;ACKNOWLEDGEMENTS;1129
7.4.4.15;CHAPTER 265. DETERMINATION OF THYMOSIN ß4 INCULTURED CELL LINES;1130
7.4.4.15.1;ABSTRACT;1130
7.4.4.15.2;KEYWORDS;1130
7.4.4.15.3;INTRODUCTION;1130
7.4.4.15.4;METHODS AND MATERIAL;1131
7.4.4.15.5;RESULTS AND DISCUSSION;1131
7.4.4.15.6;ACKNOWLEDGEMENT;1133
7.4.4.15.7;REFERENCES;1133
7.4.4.16;CHAPTER 266. SEPARATION OF CEREBROSPINAL FLUIDPROTEINS BY ANION EXCHANGE ANDREVERSE PHASE CHROMATOGRAPHY;1134
7.4.4.16.1;ABSTRACT;1134
7.4.4.16.2;KEYWORDS;1134
7.4.4.16.3;INTRODUCTION;1134
7.4.4.16.4;PATIENTS AND METHODS;1134
7.4.4.16.5;RESULTS AND DISCUSSION;1135
7.4.4.16.6;REFERENCES;1135
7.4.4.17;CHAPTER 267. FPLC FOR THE ISOLATION OF A NEWINTERMEDIATE IN THE REACTION OFTHE FIFTH (CS) AND SIXTH (C6)COMPONENT OF COMPLEMENT;1138
7.4.4.17.1;ABSTRACT;1138
7.4.4.17.2;KEYWORDS;1138
7.4.4.17.3;INTRODUCTION;1138
7.4.4.17.4;MATERIALS and METHODS;1139
7.4.4.17.5;ACKNOWLEDGEMENT;1141
7.4.4.17.6;REFERENCES;1141
7.4.5;C.5. Affinity chromatography;1142
7.4.5.1;CHAPTER 268. Na-CHANNEL PURIFICATION BY IONEXCHANGEAND AFFINITYCHROMA TOGRAPHY;1142
7.4.5.1.1;Material and Methods;1142
7.4.5.1.2;Results;1144
7.4.5.1.3;Conclusions;1144
7.4.5.1.4;References;1144
7.4.5.2;CHAPTER 269. CHROMATOGRAPHY OF PLASMAPROTEINS ON IMMOBILIZED CIBACRONBLUE, PROCION® RED AND PROCION®GREEN: USE FOR PURIFICATION OFALPHA 1-PROTEINASE INHIBITOR;1146
7.4.5.2.1;ABSTRACT;1146
7.4.5.2.2;KEYWORDS;1146
7.4.5.2.3;INTRODUCTION;1146
7.4.5.2.4;MATERIALS AND METHODS;1146
7.4.5.2.5;RESULTS AND DISCUSSION;1147
7.4.5.2.6;ACKNOWLEDGEMENTS;1148
7.4.5.2.7;REFERENCES;1148
7.4.5.3;CHAPTER 270. PURIFICATION OF HUMAN EPIDERMALGROWTH FACTOR-UROGASTRONE BYIM M UNO A FFINITY CHROMATOGRAPHY;1150
7.4.5.3.1;ABSTRACT;1150
7.4.5.3.2;KEYWORDS;1150
7.4.5.3.3;INTRODUCTION;1150
7.4.5.3.4;MATERIAL AND METHODS;1150
7.4.5.3.5;RESULTS;1150
7.4.5.3.6;DISCUSSION;1151
7.4.5.3.7;ACKNOWLEDGMENT;1152
7.4.5.3.8;REFERENCES;1152
7.4.5.4;CHAPTER 271. COMBINED PSEUDO-LIGAND AFFINITYCHROMATOGRAPHY AS A GENERALMETHOD FOR PLASMA PROTEINPURIFICATION;1154
7.4.5.4.1;ABSTRACT;1154
7.4.5.4.2;KEY WORDS;1154
7.4.5.4.3;INTRODUCTION;1154
7.4.5.4.4;MATERIALS AND METHODS;1154
7.4.5.4.5;RESULTS AND DISCUSSION;1155
7.4.5.4.6;ACKNOWLEDGEMENTS;1156
7.4.5.4.7;REFERENCES;1156
7.4.5.5;CHAPTER 272. PURIFICATION OF GLUCOCORTICOIDRECEPTOR FROM RABBIT LIVER BYSTEROID AFFINITY CHROMATOGRAPHY;1158
7.4.5.5.1;ABSTRACT;1158
7.4.5.5.2;KEYWORDS;1158
7.4.5.5.3;INTRODUCTION;1158
7.4.5.5.4;RESULTS AND DISCUSSION;1158
7.4.5.5.5;CONCLUSION;1161
7.4.5.5.6;ACKNOWLEDGEMENT;1161
7.4.5.5.7;REFERENCES;1161
7.4.5.6;CHAPTER 273. CHARACTERIZATION OF STEROIDRECEPTORS USING ION EXCHANGE FASTPROTEIN LIQUID CHROMATOGRAPHY(FPLC);1162
7.4.5.6.1;ABSTRACT;1162
7.4.5.6.2;KEYWORDS;1162
7.4.5.6.3;INTRODUCTION;1162
7.4.5.6.4;EXPERIMENTAL;1162
7.4.5.6.5;RESULTS;1163
7.4.5.6.6;DISCUSSION;1165
7.4.5.6.7;REFERENCES;1165
7.4.6;C.6. Various fractions;1166
7.4.6.1;CHAPTER 274. BINDING OF RAT LIVERGLUCOCORTICOID RECEPTOR BYHEPARIN ULTROGEL;1166
7.4.6.1.1;ABSTRACT;1166
7.4.6.1.2;KEY WORDS;1166
7.4.6.1.3;INTRODUCTION;1166
7.4.6.1.4;RESULTS and DISCUSSION;1166
7.4.6.1.5;ACKNOWLEDGEMENT;1169
7.4.6.1.6;REFERENCES;1169
7.4.6.2;CHAPTER 275. CURRENT ADVANCES IN THEPURIFICATION AND CHARACTERIZATIONOF PROGESTERONE RECEPTORS;1170
7.4.6.2.1;ABSTRACT;1170
7.4.6.2.2;KEYWORDS;1170
7.4.6.2.3;INTRODUCTION;1170
7.4.6.2.4;Acknowledgement;1173
7.4.6.2.5;References;1173
7.4.6.3;CHAPTER 276. PURIFICATION AND CHARACTERIZATIONOF THE RAT KIDNEY AND CEREBELLUM28K VITAMIN D-DEPENDENT CALCIUMBINDING PROTEINS;1174
7.4.6.3.1;ABSTRACT;1174
7.4.6.3.2;KEYWORDS;1174
7.4.6.3.3;INTRODUCTION;1174
7.4.6.3.4;RESULTS;1175
7.4.6.3.5;CONCLUSION;1177
7.4.6.3.6;REFERENCES;1177
7.4.6.4;CHAPTER 277. ISOLATION OF C1Q COMPONENT OFHUMAN COMPLEMENT „ NEW THREESTEPPURIFICATION PROCEDURE;1178
7.4.6.4.1;ABSTRACT;1178
7.4.6.4.2;KEYWORDS;1178
7.4.6.4.3;INTRODUCTION;1178
7.4.6.4.4;RESULTS AND DISCUSSION;1178
7.4.6.4.5;REFERENCES;1181
7.4.6.5;CHAPTER 278. TWO POINT TURBIDIMETRIC ALCIANBLUE TEST FOR QUANTITATIVEESTIMATION OF GLYCOSAMINOGLYCANS(GAG) IN HUMAN URINE;1182
7.4.6.5.1;ABSTRACT;1182
7.4.6.5.2;KEYWORDS;1182
7.4.6.5.3;INTRODUCTION;1182
7.4.6.5.4;MATERIAL and METHODS;1182
7.4.6.5.5;RESULTS and DISCUSSION;1183
7.4.6.5.6;ACKNOWLEDGEMENT;1185
7.4.6.5.7;REFERENCES;1185
7.4.6.6;CHAPTER 279. 5'-NUCLEOTIDASE FROM BOVINE LIVERPLASMA MEMBRANE: EFFECT OFCATIONS AND CHELATING AGENTS;1186
7.4.6.6.1;ABSTRACT;1186
7.4.6.6.2;KEYWORDS;1186
7.4.6.6.3;INTRODUCTION;1186
7.4.6.6.4;RESULTS;1186
7.4.6.6.5;DISCUSSION;1189
7.4.6.6.6;ACKNOWLEDGEMENTS;1189
7.4.6.6.7;REFERENCES;1189
7.4.6.7;CHAPTER 280. ANTIBODIES AGAINST BOVINE LIVERPLASMA MEMBRANE 5'-NUCLEOTIDASE;1190
7.4.6.7.1;ABSTRACT;1190
7.4.6.7.2;KEY WORDS;1190
7.4.6.7.3;INTRODUCTION;1190
7.4.6.7.4;RESULTS;1190
7.4.6.7.5;DISCUSSION;1193
7.4.6.7.6;ACKNOWLEDGEMENTS;1193
7.4.6.7.7;REFERENCES;1193
7.4.6.8;CHAPTER 281. HEMOGLOBIN BEIRUT ( ß126 val . ala [H4]) SYNTHESIS IN ERYTHROID CULTURES;1194
7.4.6.8.1;ABSTRACT;1194
7.4.6.8.2;KEYWORDS;1194
7.4.6.8.3;INTRODUCTION;1194
7.4.6.8.4;METHODS;1194
7.4.6.8.5;RESULTS;1195
7.4.6.8.6;CONCLUSION;1197
7.4.6.8.7;ACKNOWLEDGEMENT;1197
7.4.6.8.8;REFERENCES;1197
7.4.6.9;CHAPTER 282. CHEMOTROPIC NEOMORPHOGENESIS OFHEMODYNAMIC ALLY ACTIVEHYPERVASCULAR PATTERNS IN HARESKIN BY A MONOCYTIC POLYPEPTIDEMEDIATOR FOR BLOOD VESSELGROWTH (MONOCYTO-ANGIOTROPIN)PROMOTES TISSUE HYPERFUNCTION(HAIR GROWTH;1198
7.4.6.9.1;ABSTRACT;1198
7.4.6.9.2;KEYWORDS;1198
7.4.6.9.3;INTRODUCTION;1198
7.4.6.9.4;MATERIAL AND METHODS;1199
7.4.6.9.5;RESULTS AND DISCUSSION;1199
7.4.6.9.6;CONCLUSIONS: A NEW POSTULATE ON TUMOR GROWTH PROMOTION;1202
7.4.6.9.7;REFERENCES;1203
7.4.6.10;CHAPTER 283. LEUKOCYTIC POLYPEPTIDE WOUNDHORMONES: PHENO TYPE-SELECTIVECHEMORECRUITMENT OF BONEMARROW LEUKOCYTES INTO BLOODCIRCULATION (LEUKOCYTOSISLEUKOPENIA-LEFTWARD SHIFTREACTIONS);1204
7.4.6.10.1;ABSTRACT;1204
7.4.6.10.2;KEYWORDS;1204
7.4.6.10.3;INTRODUCTION;1204
7.4.6.10.4;MATERIAL AND METHODS;1205
7.4.6.10.5;RESULTS AND DISCUSSION;1205
7.4.6.10.6;REFERENCES;1209
7.4.6.11;CHAPTER 284. ACUTE CARDIOVASCULAR EFFECTS OFPURIFIED CLASSICAL ANAPHYLATOXININ GUINEA PIGS AND RABBITS:SYSTEMIC ACTIVITIES OF A HUMORALMEDIATOR OF INFLAMMATION RELATETO HEART MUSCLE DYSFUNCTION;1210
7.4.6.11.1;ABSTRACT;1210
7.4.6.11.2;KEYWORDS;1210
7.4.6.11.3;INTRODUCTION;1210
7.4.6.11.4;MATERIALS AND METHODS;1211
7.4.6.11.5;RESULTS;1213
7.4.6.11.6;DISCUSSION;1214
7.4.6.11.7;REFERENCES;1216
7.4.6.12;CHAPTER 285. CLINICAL ASSESSMENT OFNEUTROPENIA AND OF RESERVE POOLSOF LEUKOCYTE PHENOTYPES OFDISTINCT GRANULOPOIETICMATURATION STAGE IN BONE MARROWOF HUMANS BY PURIFIED HUMORALAND CELLULAR POLYPEPTIDEEFFECTORS FOR LEUKOCYTOSIS ANDLEFWARD SHIFT REACTIONS;1218
7.4.6.12.1;KEYWORDS;1218
7.4.6.12.2;INTRODUCTION;1218
7.4.6.12.3;MATERIALS AND METHODS;1221
7.4.6.12.4;RESULTS AND DISCUSSION;1222
7.4.6.12.5;REFERENCES;1223
8;AUTHOR INDEX;1224
9;SUBJECT INDEX;1232